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Structure of this PhD Thesis 
 
This PhD thesis is structured in accordance with the “GUIDELINES FOR PRESENTATION 
OF MASTERS AND PhD DISSERTATION/THESIS BY RESEARCH”, as approved by the 
College of Health Sciences, University of KwaZulu-Natal in 2015. It is divided into the 
following five main parts; 
 
a) Abstract 
This part is an extended summary of the entire thesis. It provides key findings of this research 
as published in peer-reviewed papers as well as those that are not yet published.  
 
b) Introduction & Literature Review 
This chapter provides an overview of major issues central to this thesis. Most importantly, it is 
an honest attempt aimed at critically-appraising the latest and seminal, as well as classical 
literature on cancer, cell death and the use of medicinal plants. It also provides opinion on 
current relevant issues and identifies gaps in the literature which provided the rationale for the 
research conducted and subsequently published.  
 
c) Materials & Methods 
This chapter explains the study-design of this research and gives information about compounds 
which were chosen. It also outlines methods and assays which were used in this research. For 
the sake of independent reproducibility of findings, this chapter describes, in detail, what was 








This chapter provides, in detail, what was discovered or the facts of this study in relation to the 
research questions. The findings are presented in figures and in written text.  
 
e) Discussion, Recommendations and Conclusion 
In this chapter, the main findings of this research are discussed and, where possible, the 
meaning of the results is explained. In addition, and where applicable, extrapolation of the 
results in a wider context is provided. A comparison of the key findings of this study with those 
from similar studies, which were carried out in both basic and clinical science settings, is done 
in this part. Furthermore, indications are provided in terms of which results were expected or 
unexpected, and an honest attempt in explaining the unexpected results is done. More 
importantly, this part contains brief points on the novelty and significance of this research.  
 
The Harvard referencing style was used and full citations are presented in the references section 
in ascending alphabetical order.  
 
All relevant additional documents are included in appendices. Notably, this section contains 
exact copies of published manuscripts which emanated directly or were written in a direct 


















Drugs derived from natural products make up a significant part of the modern pharmacopeia, but 
so far few of them came from traditional Chinese Medicine (TCM)… Quality science is the only 






































According to recent World Health Organisation (WHO) estimates, cancer causes more deaths 
than coronary heart diseases globally (GLOBOCAN, 2012). While communicable diseases 
such as HIV/AIDS continue to burden African populations, cancer is increasingly recognised 
as a critical public and private health problem in Africa (Igene, 2008). It is estimated that by 
2030, about 112 921 new cases of cancer will be diagnosed in South Africa (Singh et al., 2015). 
This would represent a 50% increase of new cancer cases as compared to 2012’s estimates by 
the WHO.  
 
Although there is little doubt about the incidences of cancer, there are, unfortunately, divergent 
theories in as far as tumourigenesis and the aetiology of cancer. Some researchers hold the 
view that cancer originates from malignant transformation of normal tissue progenitor and stem 
cells (Reya et al., 2001). Others believe that cancer is as a result of mature cells that have 
undergone de-differentiation (Sell, 2004). Notably, latest research has shown that there is a 
strong association between tissue-specific cancer risk and the lifetime cumulative number of 
cell divisions of tissue or organ-specific stem cells (Tomasetti & Vogelstein, 2015). Although 
there are still differing views on the origins of cancer, it is widely accepted that this devastating 
disease occurs as a result of abnormal cell development and is characterised by uncontrollable 
cell proliferation.  
 
The majority of currently-available cancer treatments target cell proliferation. However, the 
effectiveness of many cytotoxic drugs, including those that were discovered from plants, is 
limited by their serious side-effects and cost (Abratt, 2016). Chemotherapeutic agents that were 




roseus), etoposide (isolated from Podophyllum peltatum), paclitaxel (isolated from Taxus 
brevifolia) and topotecan and camptothecin (isolated from Camptotheca acumenata). Thus, 
medicinal plants continue to play a critical role in the management of diseases in the world.  
 
In Africa, decoctions, which contain extracts from various medicinal plants (Bruneton, 1995; 
Balunas & Kinghorn, 2005), are widely used for traditional management of many diseases 
including cancer. However, apart from subjective oral evidence regarding the effectiveness of 
extracts from various plants, the identity of ingredients, as well as the science and 
pharmacology of active compounds found in numerous popular concoctions and decoctions are 




The main objectives of this study were: 
 
 To assess anti-proliferative potential of three plant-derived-compounds, i.e. hypoxoside, 
ent-Beyer-15-en-19-ol and Z-venusol on human cancer cells, namely DU-145 (prostate), 
HeLa (cervical) and MCF-7 (breast) in vitro. 
 To determine the type of cell death, i.e. whether a compound with potential causes apoptotic 
or necrotic cell death on both human cancer and normal cell lines (such as MCF-12, 
HMECs and dMVECs). 







Materials and Methods  
 
Initially dimethylthiazol-diphenyltetrazolium bromide (MTT) assays were conducted to find 
the concentrations which may inhibit proliferation in prostate (DU-145), cervical (HeLa) and 
breast (MCF-7) cancer cells. Normal human cell lines, which were used for control purposes, 
were the primary human mammary epithelial cells (HMECs), MCF-12 and the dermal 
microvascular endothelial cells (dMVECs). Initially, cells were exposed for 48 hr to 
hypoxoside, ent-Beyer-15-en-19-ol and Z-venusol, which were isolated from Hypoxis 
hemerocallidea, Helichrysum tenax, and Gunnera perpensa, respectively.  The concentrations 
ranged from 2.34 µg/mL to 2400 µg/mL, dissolved in cell specific media. In subsequent 
experiments, the more sensitive sulforhodamine B (SRB) methodology was used, and cells 
were exposed to Z-venusol for 24 hr, 48 hr and 72 hr, to much lower concentrations, which 
ranged from 1.9 µg/mL to 240 µg/mL dissolved in dimethyl sulphoxide (DMSO).  
 
To investigate possible pathways of observed cell death, two assays were conducted. These 
were the fluorescein isothiocyanate (FITC) Annexin V apoptosis detection assay (using the 
FACS Calibur “JO” E5637 flow cytometer for analysis), and the lactate dehydrogenase (LDH) 
assay. To explore possible mechanism(s) of action, the activities of interleukin-6 (IL-6) and 
cyclic adenosine monophosphate (cAMP) were assessed. To investigate the activity of IL-6, 
cells were exposed for 48 hr to various working concentrations of Z-venusol; that is, 37.5 
μg/mL and 75 μg/mL. To investigate the activity of direct cAMP, cells were exposed for 48 hr 
to various working concentrations of Z-venusol; that is, 37.5 μg/mL, 75 μg/mL, and 150 μg/mL. 
Absorbance, which is inversely proportional to the concentration of cAMP in both the samples 




(10 µM) and propranolol (10 µM), were used separately and in combination, added to the 
highest concentration of Z-venusol for comparison.  
 
Main Results & Discussion 
 
Hypoxoside resulted in a statistically significant (p < 0.001) 38% and 77% increases in 
proliferation in MCF-7s at concentrations of hypoxoside 1200 µg/mL and 2400 µg/mL, 
respectively, after 48 hr exposure. In support of the current findings, Xulu (2013) also reported 
that hypoxoside, and its active derivative known as rooperol, significantly increases cell 
proliferation of both cancer and normal mammary cells in vitro (Xulu, 2013). This was 
considered an undesirable finding with regards to the aim of finding a cure for cancer. 
Therefore, no further test were carried out on this compound beyond the initial screening 
stages. 
 
The highest concentration (i.e., 2400 µg/mL) of the second compound, that is ent-Beyer-15-
en-19-ol, decreased proliferation in prostate cancer cells (DU-145) and in breast cancer cells 
(MCF-7) by 6% and 19%, respectively. Interestingly, much lower concentrations, i.e. 4.7 
µg/mL and 9.4 µg/mL, of ent-beyer-15-en-19-ol significantly (p < 0.05) decreased cell 
proliferation in cervical cancer cells (HeLa) by 37% and 41%, respectively. The differences in 
expression of vimentin gene, which is over-expressed in HeLa cells and suppressed in MCF-
7s and DU-145s may explain why this compound showed significant activity only in the 
cervical cancer cells (Oshima, 2002; Satelli & Li, 2011).  More importantly, the ability of this 
compound to significantly inhibit cell proliferation in the HeLa cell line by almost 50% at lower 





The findings with regards to the third compound, i.e. Z-venusol, were the most exciting. Hence 
investigations on it were developed beyond the screening stages. This compound demonstrated 
a statistically significant, concentration-dependent, apoptotic inhibitory effect on the 
proliferation of MCF-7 cells, with an IC50 of 53.7 µg/mL after 72 hr exposure, while the highest 
concentration (250 µg/mL) resulted in 69% inhibition. Both the FITC Annexin V and LDH 
results suggested that apoptosis contributed to most of the effects observed. Further, there was 
non-significant inhibition (20%) of HMEC proliferation observed when the concentration of 
Z-venusol was increased beyond 16.6 µg/mL. The highest concentration of Z-venusol used in 
this study resulted in a statistically significant (p < 0.001) 51% inhibition of IL-6 activity in the 
MCF-7 after 48 hr exposure. None of the Z-venusol concentrations, either alone or in 
combination with epinephrine, an agonist of the adrenergic receptors, showed any statistically 
significant effect on the levels of cAMP in the MCF-7s. Surprisingly, there was a significant 
(p ≤ 0.028) 34% elevation of cAMP levels in cells which were exposed to a combination of Z-
venusol and propranolol. 
 
If Z-venusol was ever able to be used clinically, there might be a need to increase the dose high 
enough for the attainment of desired therapeutic effects with minimal cytotoxicity on normal 
cells, because its potency is much lower than that of cisplatin. Increasing Z-venusol to a 
therapeutically-effective concentration would be possible as there was no plateauing-off of 
inhibition of proliferation in MCF-7s. It was only in primary normal human mammary 
epithelial cells (HMECs) that formation of “plateaus” was observed. Favourably, this selective 
plateauing-effect might allow the ‘gold-standard’ attainment of the desired cytotoxic effect on 





There are no studies with which to directly compare the findings of this study. However, reports 
on effects of the extracts of G. perpensa on various other cancer cell lines provide an 
opportunity for comparison. For instance, the results of this research support the findings of 
Simelane and colleagues. They recently reported that G. perpensa extracts caused an inhibition 
of proliferation of hepatocellular carcinoma cells (HepG2) with an IC50 of 222.33 μg/mL and 
human embryonic kidney 293 (HEK293) cells, with an IC50 of 279.43 μg/mL both after 48 hr 




Z-venusol, unlike other compounds studied, has a firm potential to play a role in the treatment 
of cancer in the future. Its mechanism of action involves IL-6 signaling, which may trigger 




o More basic science investigations using other hormone-dependent and highly 
invasive breast cancer cell lines such as the triple-negative MB-231 cells are 
needed. 
o In vivo studies, such as using the nude mice model, are needed to confirm the in 




















































1.1  Cancer 
 
Cancer is understood to be a disease which occurs as a result of aberrant cell development and 
evolution (Johnson, 2013; Komarova, 2015). Mainly, in cancer there is excess proliferation of 
cells and lack of proper differentiation thus formation of primary tumour. A benign tumour is 
a localised mass of cells with no ability to spread to other parts of the body. The cells of 
malignant tumours, however, are invasive and spread to other parts of the body or metastasise 
forming secondary tumours which cause fatal systemic disease (Cheung et al., 2016). 
 
1.1.1 Epidemiology 
According to the World Health Organisation (WHO) International Agency for Research on 
Cancer report “The GLOBOCAN 2012”, cancer is one of the leading causes of death globally 
with about 14 million new cancer cases and 8 million cancer deaths occurring in 2012 
worldwide (GLOBOCAN, 2012). Recent data show that Africa, Asia and Central and South 
America regions account for 70% of the deaths due to cancer in the world (WHO, Fact Sheet 
No: 297, 2015). Breast cancer, in particular, is the most common cancer in women and the 
second most common cancer in the world, whereas lung cancer is the most common cancer 
among males, and it accounts for the most deaths due to any cancer-type in the world (Jemal 
et al., 2011; Ferlay et al., 2015). As at January 2016, in the USA, there were an estimated 
3 560 570 and 3 306 760 females with breast cancer and males with prostate cancer, 
respectively (Miller et al., 2016).  
 
In South Africa there is gross under-reporting of cancer incidences because of lack of adequate 
national surveillance systems (Singh et al., 2015). However, most recent estimated age-




for males and females, respectively. It is predicted that in 2030, about 112 921 new cases of 
cancer will be diagnosed in South Africa, which is about a 50% increase of new cancer cases 
as compared to 2012 (GLOBOCAN, 2012). The highest ASR, 23.4 per 100 000, was estimated 
among Asian males, in South Africa, because of high prevalence of smoking among them 
(Winkler et al., 2015). About 8000 women are diagnosed annually with cervical cancer, 
representing about 19% of cancers in women, and about 4000 women per year die due to 
cervical cancer in South Africa (Tathiah et al., 2014).  The pathology-based National Cancer 
Registry in South Africa has recorded breast cancer as the most common cancer in females 
with age-standardised incidences of 25 per 100 000. Cervical cancer was recorded as the 
second most common cancers with age-standardised incidences of 20 per 100 000, respectively 
(SANCR, 2008). However, in the Eastern Cape Province, South Africa, reports extracted from 
population-based registries indicated that cervical cancer was the most common cancer 
reported in the region, accounting for about 34% of all cases (Somdyala et al., 2013). The study 
by Jemal and colleagues also places cervical cancer at the top of the most cancers in females 
in South Africa (Jemal et al., 2012). As seen internationally, prostate cancer was the most 
common cancer in males with age-standardised incidences of 24 per 100 000 in South Africa 
in 2008 (SANCR, 2008).   
 
1.1.2 Classification and Types of Cancer 
Cancer is a group of diverse diseases which can be classified into four main groups that share 
the hallmark characteristic of uncontrollable proliferation of the body’s own mutant cells (NCI, 
2015). Firstly, the carcinomas arise mainly from the epithelial cells which cover the surfaces 
of the internal and external body organs; secondly, sarcomas originate from cells found in the 




tissues of the body’s immune system; and finally leukaemia is a cancer of immature blood cells 
which accumulate in the cardiovascular system. 
 
There are many different types of cancer which affect almost all parts of human body. For 
example, prostate cancer originates from the prostate gland in males and the prostate-specific 
antigen (PSA) plays a critical role in diagnosis of prostate cancer (Stephenson et al., 2006). 
More than 95% of prostate tumours are adeno-carcinomas that start in acinar wall and proximal 
ductal epithelium (Zelefsky et al., 2011); prostate cancer is more prevalent in men who are 60 
years and older (GLOBOCAN, 2012).   
 
Cervical cancer often occurs where the uterus meets the vagina. Infection with human 
papilloma virus (HPV), which occurs mainly during unprotected heterosexual intercourse, is 
the main cause of cervical cancer (Herbert & Coffin, 2008). The HPV initially infects the basal 
cells of mucosal or epidermal epithelium. Some HPVs can alter cell structures in the body, 
eventually becoming cancerous. There are more than 100 oncogenic strains of HPV, but the 
strains found in more than 50% of cases of cervical cancers are HPV 16 and 18 (WHO Fact 
Sheet No.: 380, 2015). HPV vaccines have been developed and are usually targeted at 
adolescents who are not yet sexually active (Saslow et al., 2007). Although sporadic cases of 
venous thromboembolism (VTE) have been reported (Liu et al., 2016), these vaccines offer 
protection against strains of HPV infections that cause more than 70% of cases of cervical 
cancer (ACS, 2011). 
 
Breast cancer can occur both in males and females, although it is very rare in males. The 
mammary carcinoma, a mixture of both ductal and lobular breast cancers, is the most common 




or tubes that carries milk to the nipples and they account for more than 80% of all mammary 
carcinomas while the lobular carcinomas originate from the milk-producing lobule tissues 
(ACS, 2011). Breast cancer can also begin in the stromal tissues, which include the fatty and 
fibrous connective tissues of the breast, but that accounts for less than 2% of invasive breast 
cancers (Makki, 2015).  Clinically, breast cancer can be divided into three subgroups; oestrogen 
receptor positive (+ER), HER2 positive, and triple-negative which refers to the absence of ER, 
progesterone receptor (PR) and HER2 (Rimawi et al., 2015). HER2 protein increases 
proliferation of breast cancer cells and it is over-expressed in 20% of breast tumours 
(Mustacchi et al., 2015). Therefore, in therapeutics HER2 protein is often the main target of 
therapy when drugs such as trastuzumab and lapatinib are used in patients with breast cancer 
(Zanardi et al., 2015).  
 
1.1.3 Causes of Cancer 
There are many theories that attempted to explain tumorigenesis, especially at molecular level. 
These theories, however, can be divided into two main schools (Rivlin et al., 2011). The first 
group, or the old and widely-held school, maintains that cancer is as a result of normal, less or 
non-differentiated cells that have acquired additional traits which render them aggressive. The 
second school suggests that tumour is initiated by the stem cells with oncogenic properties 
(Reya et al., 2001; Max, 2003; Dean et al., 2005; Wu, 2008).  
 
For many years, there were only two factors considered as the main causes of cancer; 
environmental factors (e.g., the use of tobacco, alcohol and unhealthy lifestyles, the so called 
“modifiable risk factors”) and genetic predisposition (WHO, Fact Sheet No: 297, 2015). 
However, recently, Tomasetti & Vogelstein (2015), brought the theory of “cancer stem cells” 




a result of accumulation of mutations, a small population of cells acquire limitless capability 
for self-renewal and the ability of these to cause indefinite proliferation play a vital role in 
tumorigenesis (Marx, 2003; Wang & Dick, 2005).  CSCs possess self-renewal properties that 
the physiological embryonic stem cells (ESCs) and the adult stem cells (ASCs) exhibit (Alvarez 
et al., 2012). In addition, however, CSCs’ are very small in size; they have slow rate of division; 
they have high expression of ATP-binding cassette (ABC) transporters, telomerase and key 
stem cell genes (e.g., SOX2); they have the ability to remain dormant for lengthy periods; and 
they are resistant to chemotherapy (Alvarez et al., 2012; Clevers, 2016).  Therefore, Tomasetti 
& Vogelstein proposed that different regenerative capacities of tissues and the “stochastic 
effects” may play a critical role in aetiology of the majority of cancers. For example, in organ-
specific cancers such as the colorectal and intestinal cancers, the genetic and environmental 
predispositions inadequately explain differences in risk in human beings. The regenerative 
capacities of tissues, which usually proliferate rapidly from the stem cells, are biologically 
more likely to have mutations. Therefore, Tomasetti & Vogelstein strongly maintain that 
cumulative number of DNA replications and the rates of stem cells division that happen in a 
life-time are the major causes of organ-specific cancer types in human beings (Tomasetti & 
Vogelstein, 2015). 
 
The findings of Tomasetti & Volgelstein, especially their main conclusion that about 66% cases 
of cancer cases are as a result of “bad-luck” created debates in both lay media (Wright, 2015; 
Knapton, 2015; Boseley, 2015; Alexander, 2015), and in academic fields (O'Callaghan, 2015; 
Ashford et al., 2015; Gotay et al., 2015; Couzin-Frankel, 2015; Wild et al., 2015; Wodarz & 
Zauber, 2015).  As a result, the WHO’s International Agency for Research on Cancer issued a 
press release strongly disagreeing with Tomasetti & Volgelstein’s conclusions (WHO Press 




molecular events involved in cancer, they affirmed the public health agenda’s role in promotion 
of healthy lifestyles and reduction of tobacco smoking efforts (Lancet Editorial, 2015; 201). 
O'Callaghan (2015) stated that it is possible that Tomasetti & Volgelstein missed a huge 
volume of data by not having used a systematic literature review or meta-analysis 
methodologies, because they did not include more aggressive and common cancers such as 
those of the breast and prostate.  
 
However, many other researchers have embraced the Tomasetti & Volgelstein’s proposal as a 
tissue micro-environment factor, which is valuable in the growth of transformed cells. 
Therefore, Crossan and colleagues suggest that the Tomasetti & Volgelstein’s proposal deserve 
to be explored in order to understand how tumorigenesis occurs (Crossan et al., 2015). It 
appears that when genetic and environmental factors cannot fully explain why there are huge 
variations of cancer risk for different organs that are often exposed to the same potential 
mutagens or have the same inherited mutant genes (Crossan et al., 2015; Albini et al., 2015). 
Although CSCs have been implicated in the aetiology of prostate, cervical and breast cancers 
(Wang & Dick, 2011; Yao 2015), unfortunately, Tomasetti & Volgelstein’s study did not 
include these common cancers in their analysis. However, regardless of the causes, the 
incidences of certain cancer (especially breast cancer in women) increase with age (Colditz et 
al., 2014). 
 
A substantial number of cancers have also been associated with chronic inflammation. These 
include cervical, ovarian and oesophageal cancers, among many (Balkwill & Mantovani, 
2001). Tumour-associated macrophages (TAM) and pro-inflammatory cytokines such the 
interleukins (IL) 1 & 6, tumour necrosis factor (TNF) and nuclear factor-kappaβ (NF-κβ) play 




have showed that TNF require STAT3, a gene which plays a critical role in cell proliferation, 
for carcinogenesis, especially in colon cancer (Lee et al., 2009). 
 
1.1.4  Characteristics of Cancer Cells 
The cells that make-up primary tumours can differ in terms of growth rate, drug sensitivity, 
metastatic potential and their prevalence (Hanahan & Weiberg, 2000; Huysentruyt & Seyfried, 
2010). Generally cancer cells show at least five characteristics, which separate them from 
normal cells, namely: 
 
1.1.4.1  They have uncontrollable proliferation 
In cancer cells, the processes that usually control cell division and tissue growth do not 
adequately regulate cell proliferation. This can be due to abnormal production of, or responses 
to, growth factors or to altered feedback controls, such as increased cell activity. This increase 
may be caused by malfunctioning of cyclin-dependent kinases (CDKs) and/or Ras and/or other 
genes leading to genomic instability (Schwab, 2009; Gordeon et al., 2011). Mutations in the 
p53 gene, a member of the super tumour suppressor gene (TSG) family which are responsible 
for terminating cell division and proliferation once DNA is damaged, accounts for most cases 
of tumorigenesis (Rivlin et al., 2011).  
 
Excess proliferation could also be the result of loss of Wnt proteins’ signalling activity in the 
nearby aberrant or injured cells (Frede & Jones, 2013; Lim et al., 2013). Usually, in tumour 
cells, as well as in normal cells when Wnt signalling pathway is activated, there is a loss of 
Wnt genes (Komiya & Habas, 2008). Therefore, proteasomes remain inactive, resulting in 
accumulation of β-catenin proteins. In turn, high level of β-catenin proteins increases 





Uncontrollable proliferation is also caused by decreased cell death due to diminished activity 
of apoptotic protease activity factor 1 (APAF-1), which normally binds to the “initiator” 
cysteine aspartate protease enzymes 9 (caspase-9) to activate the “executioner” caspase-3 (Sun 
& Peng, 2009). Decreased cell death can also be due to an increased activity of the B-cell 
Leukemia/Lymphoma gene (Bcl-2) and many other mediators which play a meaningful role in 
cell survival and apoptosis (Weinberg, 2007). It has also been recently reported that cancer 
cells, unlike normal cells, have the ability to proliferate indefinitely even after centrosome loss 
(Stearns, 2015; Wong et al., 2015), making the achievement of efficacy with medicines which 
inhibit proliferation medicines, such as vinblastine, arduous and complex. 
 
1.1.4.2  They lose the ability to differentiate and function 
In normal cells, cell multiplication involves division of the stem cell in a particular tissue to 
give rise to daughter cells. These daughter cells ultimately differentiate to become mature cells 
of the relevant tissue and carry out organised functions (Berthron, 1992). The transforming 
growth factor-beta (TGF-β) superfamily, and the Activin A gene, in particular, play an 
important role in differentiation processes in normal cells (Moses & Serra, 1996). Therefore, 
deregulation of TGF-β genes causes less cell differentiation and contribute to cancer 
progression and invasion (Loomans & Andl, 2014). Helczynska and colleagues have reported 
that, in breast cancer, high levels of hypoxia-inducing factors, such as the HIF-1, inhibit cell 
differentiation (Helczynska et al., 2003).  In colon cancer, cells lose their capacity to 
differentiate due to defects in the adenomatous polyposis coli (APC) gene and therefore are 






1.1.4.3  They expand and invade other tissues 
Normal cells throughout differentiation and during the growth of tissues and organs, develop 
certain spatial relationships with respect to each other. This relationship is continually 
maintained even when the cells are involved in repair. However, cancer cells “acquire” the 
ability to invade other tissues (Weinberg, 2007). Mediators, such as the matrix 
metalloproteinases (MMPs), play a critical part (Corcoran et al., 1996; Parsons et al., 1997; 
Kähäri and Saarialho-Kere, 1999; Hua et al., 2011). Recently, Hammer & Diakonova have 
showed that serine-threonine kinase p21-activated kinase-1 (PAK1) increases motility and 
stimulates invasion of breast cancer cells in response to prolactin via transcription and secretion 
of MMP-1 and MMP-3 (Hammer & Diakonova, 2015). 
 
1.1.4.4  They undergo metastasis  
About 90% of deaths due to cancer are caused by metastasis (Gilkes et al., 2014). Metastases 
are secondary tumours formed by cancer cells that have been released from the initial tumour 
and travelled to another site in the body. They spread via the lymphatic system, through open 
cavities, such as the pleural cavity or abdominal cavity (peritoneal metastases), and through 
the blood stream (Schwab, 2009). For the metastasised cell to multiply at new sites, tumour 
angiogenesis takes place. During angiogenesis, vascular endothelial cells, which normally 
multiply very slowly, proliferate rapidly to form new capillaries which supply cancer cells with 
nutrients (and oxygen) and remove waste products (NCI, 2011).  Vascular endothelial growth 
factor (VEGF) is one of the proteins which plays a critical role in tumorigenesis and in the 
spread of malignant cells in solid tumours (Taniguchi et al., 1998). At clinical level, other 
microenvironment factors that plays a critical role in metastasis is hypoxia and expression of 





The contents of the extracellular matrix (EMC) also play an important part in metastasis (Gilkes 
et al., 2014). EMC is a complex meshwork which contains over 300 different proteins that 
serve many roles which include regulating intercellular communication (Naba et al., 2012). 
These proteins enable cancer cells to migrate to distant sites and to survive even when there is 
insufficient oxygen and they also stimulate VEGF, which ultimately causes angiogenesis. More 
importantly, Boyd and colleagues have showed that EMC stiffness increases the risk of breast 
cancer and resistance to treatment (Boyd et al., 2014). 
 
It has been widely reported that, in many epithelial tumours, the epithelial-mesenchymal 
transition (EMT), a pathologic process which enhances the motility and migratory properties 
of epithelial cells, is crucial for metastasis and lethality of cancer (Micalizzi et al., 2010; Britton 
et al., 2011; Chao et al., 2012; Mallini et al., 2014). On the contrary, the latest studies show 
that although EMT causes cancer resistance to chemotherapy, it has no significant role in the 
many metastatic cancers (Zheng et al., 2015; Fischer et al., 2015). Therefore, more research is 
needed to clarify the role of EMT in the metastatic ability and the deadliness of epithelial breast 
cancer cells in particular.  
 
1.1.4.5  They have altered metabolism – the “Warburg effect” 
Normal mammalian cells produce energy in the form of adenosine triphosphate (ATP) by 
catalysing the conversion of glucose or fructose to pyruvate during glycolysis. In the presence 
of oxygen pyruvate molecules enter the mitochondria to produce 36 additional units of ATP. 
However, in cancer cells, even when there is sufficient oxygen, there is accumulation of lactate 
and only two additional molecules of ATP are produced from pyruvate; this is called “aerobic 
glycolysis” or the “Warburg effect” (Warburg, 1931). Although the exact cellular mechanisms 




metabolism of glucose by various cancer cell-lines is more than an adaptation to hypoxia. For 
example, it has been reported that non-invasive MCF-7 breast cancer cells have much lower 
aerobic glucose consumption rates compared to the highly invasive MDA-MB-231 breast 
cancer cell line during normoxia and hypoxia (Gatenby & Gillies, 2004).  
 
The metabolism of glucose to pyruvate without mitochondrial respiration requires the enzyme 
lactate dehydrogenase (LDH) to produce increased amounts of lactate and regenerate 
nicotinamide adenine dinucleotide (NAD) from nicotinamide adenine dinucleotide hydrogen 
(NADH) (van der Heiden, 2011). There is also increased glucose consumption and decreased 
oxidative phosphorylation, which are also features of oncogene activation (Warburg, 1931; 
Gatenby & Gillies, 2004). Shifting to aerobic glycolysis diminishes dependence of cancer cells 
on oxygen and it gives these cells an advantage over normal cells as they continue to proliferate 
(Gatenby & Gillies, 2004). This leads to “stabilization” of hypoxia-inducible transcription 
factor (HIF), which then up-regulates VEGF to promote angiogenesis (Hsu & Sabatini, 2008). 
Deranged metabolism in cancer cells increases biosynthesis of nucleotides, proteins, 
phospholipids, fatty acids and inhibits apoptosis, while glucose transporters (GLUT-1) are used 
to remove toxic metabolites and lactate (Larson et al, 2011).  
 
1.1.5  Treatment of Cancer 
Depending on the size and the location of the tumour, approaches for treatment include surgery 
and irradiation therapy, especially for localised lumps. Alternatively there is chemotherapy, 
whereby cytotoxic drugs are used before (i.e., primary or neoadjuvant) or after (i.e., secondary 
or adjuvant) tumour mass has been reduced with radiation and/or surgery (Lippman et al., 





1.1.5.1  Origins of cytotoxic drugs and classification of chemotherapy  
Systemic medicines that are used to treat cancer vary extensively in terms of whether they were 
initially derived from inorganic and metal-based compounds or from plants. They also vary in 
terms of their effectiveness and their ability to increase survival rates in humans. Both the 
inorganic agents, cisplatin (a platinum-based cytotoxic drug) and cyclophosphamide are 
alkylating agents. Cyclophosphamide, the most commonly used anticancer drug, is a pro-drug 
converted to an active metabolite by hepatic enzymes (Ludeman, 1999). Acrolein, 
cyclophosphamide’s active metabolite, causes damage to urinary bladder (Kehrer & Biswal., 
2000). Other side effects of cyclophosphamide include: Marked immune-suppression, 
leukopenia (sometimes called leukocytopenia; a reduced number of leukocytes) and 
cardiotoxicity (Hassan & Waller., 2015). Although cisplatin has a broad spectrum of action in 
cancer chemotherapy, it causes debilitating side effects such as nausea, vomiting and 
thrombocytopenia (Dasari & Tchounwou 2014; DeLozier et al., 2014; Gresham et al., 2014). 
Other systemic treatment includes hormonal therapy such as anastrazole, tamoxifen for breast 
cancer (Dalmau et al., 2014); androgen synthesis inhibitors such as abiraterone acetate for 
prostate cancer (Wolff et al., 2015; Zhang et al., 2015).  
 
Recent advances in targeted cancer treatment include immunotherapy and the use of biological 
medicines. A number of potential immunotherapy agents have been reported to work through 
the immunoglobulin superfamily; the extracellular immunoglobulin V (IgV) domain, the T cell 
immunoglobulin and mucin domain (TIM) play a critical role in tumorigenesis (Baghdadi & 
Jinushi, 2014). Accumulation of TIM-3 gene within the tumour micro-environment, reduces 
anti-cancer immune-surveillance by producing inhibitory signals which causes apoptosis of T 
helper (Th-1) cells (Freeman et al., 2010). Therefore, evidence from pre-clinical studies 




and targeted therapies (which are generally classified into the monoclonal antibodies such 
bevacizumab and the protein kinase inhibitors such as imatinib) increase survival especially 
when used in combination with chemotherapy or cytotoxic drugs (Sikic, 1999; Liauw, 2013).  
 
Since it was established that cAMP is upregulated in cancer cells, in both in vitro and in vivo 
studies (Lang et al., 2004), there have been many studies that have evaluated the effectiveness 
of β-adrenergic blockers in patients with cancer. For instance, several studies have reported 
that propranolol suppresses angiogenesis (Lamy et al., 2010), is safe and effective against 
various vascular tumours such as has haemangioma in infants (Bayart & Brandling-Bennett, 
2015); it reduces triple-negative breast cancer brain metastases (Bai et al., 2010; Choy et al., 
2016); it reduces breast cancer progression and mortality (Barron et al., 2011); it enhances the 
efficacy of other cytotoxic drugs (Pasquier et al., 2011); and it improves survival  (Powe et al., 
2011). 
 
To improve the outcomes and to prevent drug-resistance, there are various chemotherapy 
regimens, or combinations of drugs, applied in the treatment of cancer. Firstly, there are typical 
or conventional regimens whereby maximum doses, over a controlled number of treatment 
cycles that can be tolerated, are administered to kill as many cancer cells as possible (Swain et 
al., 1987). Secondly, there are intermittent regimens whereby maximum doses are administered 
until the tumour diminishes whereupon therapy is stopped or missed and started once again 
should the cancer re-emerge (Enriquez-Navas et al., 2015). Thirdly, there are adaptive 
regimens whereby individualised treatment schedules are adapted from time to time depending 





1.1.5.2  Currently used plant-derived cancer drugs 
Vincristine, vinblastine and vinorelbine, originally derived from Catharanthus roseus, act by 
binding to tubulin proteins during an M-phase and thereby prevent formation of spindles that 
are essential for the centriole duplication and ultimately resulting in the formation of daughter 
cells (Silverman & Deitcher, 2013; Wong et al., 2015).  Other regularly-used anti-cancer drugs 
originally derived from plants include paclitaxel (isolated from Taxus brevifolia), topotecan 
(isolated from Camptotheca acuminata), etoposide (isolated from Podophyllum peltatum) and 
camptothecin (isolated from Camptotheca acumenata) (Wall et al., 1966). These agents, the 
“taxanes”, act by inhibiting telomerase, a reverse transcriptase enzyme, which is upregulated 
during mitotic cell division in cancer cells (van Vuuren et al., 2015).  Therefore, medicinal 
plant derivatives continue to play an important role in the current management of many 
diseases, including cancer, as it also happened in the past (Rates, 2001). 
 
1.1.5.3  Plant-derived compounds with cytotoxic potential 
Recently, many compounds, some extracted from various indigenous South African plants, 
have been reported to have anti-bacterial, anti-inflammatory and anti-tumour effects (Watt & 
Breyer-Brandwijk, 1926; Hutchings, 1989; Fouche et al., 2008). These indigenous plants and 
their relevant compounds include Agapanthus africanus (which contains saponins and 
sapogenins), Bulbine natalensis (chrysophanol and knipholone), Gunnera perpensa (which 
contains flavonoids), Helichrysum species (flavonoids), Pallaea calomelanos (triterpenoid 
saponins), Heteropyxis natalensis (limonene, ocimene and cineole), Plumbago auriculata 
(plumbagin), Sanseviera hyacinthoides (sapogenin and ruscogenin), Scilla natalensis (saponins 
and homoisoflavanoids), Trichilia emetica (limonoids), Tulbagia violacea (alliin), 




(saponins and sapogenins) and Gunnera perpensa (Hutchings et al., 1996; van Wyk et al., 
1997). 
 
Traditional uses of extracts from Hypoxis hemerocallidea (of the plant family Hypoxidaceae), 
commonly known the “African potato”, include the management of conditions such as 
inflammation, diabetes and convulsion is common in South Africa (Laporta et al., 2007). There 
is evidence that suggests that pure compounds too, especially hypoxoside and rooperol (Figure 
1.1), pentenyne derivatives, isolated from H. hemerocallidea have a role to play in the 
management of cardiovascular diseases (Coetzee et al., 1996), mycobacterial diseases 








Figure 1.1: Structure of hypoxoside, which transforms into a more active metabolite (rooperol) 






Helichrysum petiolare, also known as impepho in isiZulu, is the most well-known member of 
the genus Helichrysum (of the plant family Asteraceae), and is widely distributed throughout 
South Africa. The dried plant is often burned because the resultant smoke is used as a ritual 
incense. Plant decoctions are used traditionally to treat cough, fever, infection and menstrual 
pain (Hutchings et al., 1996; van Wyk et al., 1997). The active ingredients of H. petiolare, have 
anti-inflammatory and antitumour (inhibiting cyclin B/cdc2 kinase enzyme) activities 
(Kobayachi et al., 2002).  While traditional uses of crude extracts of H. tenax include treatment 
of sore eyes (Lourens et al., 2008),   ent-beyer-15-en-19-ol (Figure 1.2), a diterpenes, isolated 
from the leaves of H. tenax was active against pathogens such as Bacillus cereus and 















Figure 1.2: Structure of ent-beyer-15-en-19-ol isolated from the leaves of Helichrysum tenax 





Gunnera perpensa (of the plant family Gunneraceae), also known as “river pumpkin”, ughobo 
or uklenza (isiZulu), ipuzi lomLambo (isiXhosa) and qobo (Sesotho), grows well along the river 
banks in many parts of South Africa (Khan et al., 2004). Its traditional uses (in decoctions; that 
are water-filtered from boiling the finely ground parts of the plants for a specified period of 
time) by African traditional healers vary widely and include; maternal/foetal ailments, other 
conditions such as: painful joints, “canker sore”, rheumatism and swelling (Iwalewa et al., 
2007; Ndhlala et al., 2011), breast (Seleteng-Kose et al., 2015) and stomach cancer (Pujol, 
1990), psoriasis (Hutchings et al., 1996), wound dressing (Grierson & Afolayan, 1999), 
diarrhoea and for treatment and eradication of intestinal parasites (McGaw et al., 2000). Khan 
et al., (2004), isolated and identified Z-venusol (molecular formula – C15H16O8, molecular 
weight – 324.28 gmol-1), a phenylpropanoid glycoside (PPG), as the main active compound 
found in the roots of G. perpensa (Figure 1.3). Subsequently, Drewes et al. (2005) isolated a 
1,4 benzoquinone compound from G. perpensa’s fresh stems and leaves (collected in spring), 
and reported that it inhibited the growth of various pathogens, such as Staphylococcus 
epidermidis, Enterococcus faecalis, Staphylococcus aureas and Bacillus cereus. In 1997 Kaido 
and colleagues reported that a G. perpensa (dried roots boiled in distilled water for 4 hr) extract 
potentiated an oxytocin-like response to rat uterine contractions (Kaido et al., 1997). Thus, it 
is encouraging that recent studies are not only reporting on the claims or on traditional uses 
associated with G. perpensa, but are scientifically verifying some of these claims (McGaw et 






















Although there is evidence that support the claims attributed to the effectiveness of many plant 
extracts against various diseases, including cancer, the strength of such evidence needs to be 
investigated (Mathibe, 2015). Recently, the Medicines Control Council (MCC) in South Africa 
published “draft guidelines”, which propose that evidence be provided on the effectiveness of 
products’ active ingredients and their excipients before registration and sale is allowed (MCC, 
2015) Unfortunately, while awaiting the promulgation of the law which will regulate the use 
of traditional medicines, many unregistered herbal products and concoctions are commonly-
used in South African (van Wyk, 2008). Fortunately, huge national effort is now being put into 
establishing a scientific basis for understanding how compounds derived from plants stop 
proliferation of cancer cells and how they cause cell death in cancer and normal cells.  
 
1.2  Cell Death 
 
For many years, cell death was divided into necrosis and apoptosis (Kerr et al., 1972; Karantza 
& White, 2011). Necrosis is characterised by cell membrane rupture and the release of 
organelles which are non-functional, while during apoptosis the membrane remains intact and 
the DNA fragments into small pieces (Nanji, et al., 1997). Initially, necrosis was considered as 
a bad or “passive” and uncontrolled process of cell death, as compared to apoptosis, an epitome 
of “programmed cell death” (PCD).  However, recent studies have demonstrated that PCD can 
occur in at least three distinct types, namely; apoptosis, autophagy and necroptosis (Clarke, 






1.2.1  Type I Programmed Cell Death – Apoptosis 
Apoptotic cell death, a process which was first reported by Kerr and colleagues in 1972, 
involves activation of a serial cascade of different caspases which act “upstream” or as 
initiators (caspases 8, 9 & 10) and those that act at “downstream” or as executioners (caspases 
- 3, 6 & 7) of cell death (Kerr et al, 1972; Thornberry & Lazebnik, 1998). Cell death could 
happen through either the intrinsic or the extrinsic pathway. The intrinsic pathway involves 
mitochondria while the extrinsic pathways happens via activation of the cell surface receptors 
(Kerr et al., 1972; Kroemer et al., 2007).  
 
Briefly, a complex intrinsic pathway is activated when the mitochondrion receives apoptotic 
signals when DNA is damaged. These signals activate the oligomerisation proteins which 
include Bcl-2 associated proteins, which in turn increases mitochondrial outer membrane 
permeability (MOMP). The MOMP activates the release of cytochrome c (Cyt-C) which in 
turn activates Apaf1. Induction of Apaf1 protein activates the release of caspases 3 and 7, which 
ultimately causes cell death (D'Amelio et al., 2010; Mirzayans et al., 2016).  
 
The extrinsic pathway is activated by the tumour necrosis factor super-family, which comprise 
tumour necrosis factor alpha (TNF-α), the tumour necrosis factor-related apoptosis-inducing 
ligand (TRAIL) and the Fas ligand (FasL), among others (Kroemer et al., 2007). Signals from 
these protein trigger the membrane-bound death-inducing signalling complex (DISC) to induce 
caspases 3 and 8 directly (Nicholson & Thornberry, 1997; D'Amelio et al., 2010).  In vitro 
studies have shown that DNA fragmentation associated with apoptosis occurs through 
activation of caspase 7 in cells that are caspase 3 deficient such as the MCF-7s (Kagawa et al., 





1.2.2  Type II Programmed Cell Death – Autophagic Cell Death 
In autophagic cell death, autophagosomes bind to lysosomes to form a double membrane 
around the cell organelles and subsequently the sequestered cell is digested (Tsujimoto & 
Shimizu, 2005; Kuo, 2006).  Autophagy can be stimulated by hypoxic conditions and high 
temperature. It is often used by the cells as a temporary survival strategy (Karanza & White, 
2011), but an up-regulation of the autophagy-related genes (Atg5 & Atg6), as was 
demonstrated by Tsujimoto & colleague (Figure 1.4),  leads to cell death (Tsujimoto & 
Shimizu, 2005). Although many studies have focused on the autophagic processes in the 
cytoplasm, recently Dou and colleagues (2015) reported that nucleic lamin B1 degradation 
during “oncogenic insults” induces autophagic cell death to protect cells from tumorigenesis 






















Figure 1.4: A cascade showing survival of cell and autophagic cell death (by 
Tsujimoto & Shimizu, 2005) as a result of different concentrations of autophagy-
related genes (Atg5 & Atg6). When there is a low concentration of level of Atg5 & 




1.2.3  Type III Programmed Cell Death – Necroptosis or Pyroptosis 
Necroptosis, or programmed-necrosis is initiated by the death domain proteins such as the TNF 
family, the interleukin (IL-6) gene and the receptor-interacting proteins (RIP-1 and RIP-3) 
(Wallach et al., 2016), and it can take place independent of caspases (Sperandio et al., 2000; 
Broker et al., 2005; Kroemer et al., 2009). Its execution involves the active disintegration of 
mitochondrial, lysosomal and plasma membranes (Vandenabeele et al., 2010). Fink & 
Cookson (2005) proposed the use of the term “pyroptosis” in reference to cell death which 
involves both caspases and inflammatory cytokines such as IL-1 and IL-8; further, these 
authors define pyroptosis as a pro-inflammatory pathway resulting from caspase-1 activity 
leading to membrane breakdown and pro-inflammatory cytokine processing (Fink & Cookson, 
2005). Another cytokine, which plays a crucial role in pyroptosis and facilitates deadly changes 
in the cell, is the mixed lineage kinase domain-like protein (MLKL). This is thought to be a 
pro-inflammatory cellular component (Wallach et al., 2016).   
 
In human beings and in in vivo studies, apoptosis is not complete until phagocytes remove or 
dispose of dead cells (deCathelineau & Henson, 2003). Therefore, the final stage of apoptosis 
is characterised by the release of the lysophosphatidylcholine (LPC) and phosphatidylserine, 
the “find-me” and “eat-me” signals, respectively (Hochreiter-Hufford & Ravichandran, 2013). 
Thus, these signals appear on the surfaces of the dead cells for the phagocytes to remove dead 
cells and to prevent inflammation (Grimsley & Ravichandran, 2003; Lauber et al., 2004). 
Inflammation happens during necroptosis as a result of activation of damage-associated 
molecular patterns (DAMPs) and the NLRP3 inflammasome gene (Kang et al., 2014; Lawlor 
et al., 2015). Recently, Yoon and colleagues have reported that the p53 gene, in addition to 
controlling proliferation and inducing apoptosis, also plays a significant role in the removal of 




1α” (DD1α), a member of the immunoglobulin family, to appear on the surfaces of dying cells, 
thereby avoiding inflammation by enabling removal of dying and dead cells  (Yoon et al., 2015; 
Zitvogel & Kroemer, 2015).  
 
Recently, Newton and colleagues have demonstrated that both apoptosis and programmed 
necrosis involve the intersection of receptor-interacting protein kinase 3 (RIPK3), and they 
further illustrated how unsettling one pathway can incite death by the other (Newton et al., 
2014; Zhang & Chan, 2014). Therefore, it is clear that various pathways complement each 
other for both the demise of cells and clearance of “dead cells” once death has occurred. 
 
1.3  Assessing Cell Proliferation, Turnover and Cell Death 
 
There are various colourimetric assays used to assess cytotoxicity of various plant extracts and 
pure compounds on cells in vitro. These include the tetrazolium salt, 3-4,5 dimethylthiazol-2,5 
diphenyl tetrazolium bromide (MTT) assay (Mossman, 1983;  Twentyman & Luscombe, 1987) 
and the sulforhodamine B (SRB) assay (Skehan et al., 1990), lactate dehydrogenase and 
Annexin V assay (del Bino et al., 1999). Studying mechanisms of action of drugs is 
complicated by the fact that observed effects are as a result of complex interactions of 
compounds with various proteins and metabolites (NRC, 2007; 109).  Thus, there many assays 
used to explore mechanism of action of compounds with potential health benefits. These 
include the caspase, cAMP and IL-6 assays (Madden et al., 2011).   
 
1.3.1  Colourimetric Assays 
In the MTT assay, the soluble yellow tetrazolium salt is reduced in metabolically active/viable 




SRB assay, the bright-pink aminoxanthene SRB dye adheres to basic-amino acid residues 
under mildly-acidic conditions and dissociates under alkaline conditions. The SRB dye from 
stained cells is directly proportional to cell density (Vichai & Kirtikara, 2006).  Recently, Sodde 
and colleagues have demonstrated that the sensitivity of the SRB assay is better than that of the 
MTT assay in studies assessing proliferation of MCF-7 breast cancer cells in vitro (Sodde et 
al., 2015).  Other ways of assessing cell death in vitro, are to use other chromagen-based assays 
such as the lactate dehydrogenase (LDH) assay (King, 1965), the cysteinyl-aspartic acid 
proteases (caspase) assay (Debatin, 2004) and the Annexin V assay.  
 
The main function of LDH is to convert pyruvic acid into lactic acid (Guyton, 1991: 751). In 
the presence of diaphorase, LDH converts lactic acid back into pyruvic acid. LDH is mainly 
found inside the cell and high concentrations in the extracellular fluid are indicative of cell 
membrane damage and cell death.  
 
Caspase activity assay involves a series of steps which involve cleaving a tetrapeptide which 
gives measurable colourimetric signal. Briefly, as caspases become activated, they split 
specific substrates either activating or inactivating them. Ruptured substrates bind to a 
preferred tetrapeptide cleavage sequence at the aspartate residue. Ultimately, a cleaved 
substrate produces a colourimetric signal, which is an indication of caspase activity (Roche, 
2003; Schulze-Osthoff, 2008). 
 
With a flow cytometer, the uptake of Annexin V and propidium iodide (PI) dyes, at the 
beginning of cell death, has been used to differentiate between cells undergoing apoptotic and 
necrotic cell death (del Bino et al., 1999; Yue et al., 2010). As the process of death starts, cells 




particular mechanism of death. Cells undergoing early necrosis absorb only the PI dye and are 
therefore dispersed in the upper left quadrant, while cells undergoing early apoptosis are in the 
lower right quadrant as the Annexin V dye attaches to the phosphatidylserine (PS) protein 
exposed to the outer surface of the cell membrane. Cells in late apoptosis and/or necrosis, are 
dispersed into the right upper quadrant because they absorb both the PI and the Annexin V 
dyes. 
 
1.3.2 Assays used to explore mechanism of action of compounds 
Cyclic nucleotides such as cAMP and cyclic guanosine monophosphate (cGMP), have both 
been reported to have effects on breast cancer cell proliferation and apoptosis.  Elevation of 
cGMP activity inhibits proliferation and induces apoptosis of breast cancer cells (Follin-
Arbelet et al., 2011; Dong et al., 2015). However, the effects of cAMP have been more 
contentious, with cAMP reported to either stimulate or inhibit proliferation depending on the 
type of the cancer cells studied (Kung et al., 1983; Fentiman et al., 1984). The assay uses 
polyclonal antibody to bind to free cAMP in the sample and the intensity of the yellow colour 
generated is inversely proportional to the cAMP concentration.  
 
Interleukin 6 (IL-6) is a pleiotropic cytokine produced by many different types of cells (Adams 
et al., 1991; Saglam et al., 2015).  IL-6 has the ability to upregulate VEGF and its high 
concentration is associated with shorter survival in various patients with prostate and breast 
cancer (Bachelot et al., 2003). The IL-6 activity immunoassay utilises tetramethylbenzidine 
(TMB) substrate to indicate the concentration of IL-6 in the supernatants, plasma and other 






1.4  Cell Lines 
 
Various in vitro models are available and an appropriate cell line can be chosen when studying 
different cancers (Holliday & Spires, 2011).  The DU-145, HeLa, and MCF-7 cell lines are 
well characterised and have been used regularly to study prostate, cervical and breast cancer 
respectively in human beings. Along with cancer cell lines normal cell lines such as human 
dermal micro-vascular endothelial cells (dMVECs) and mammary epithelial cells (HMEC and 
MCF-12A), are available to use as controls. 
 
The prostate cancer DU-145 cells were originally derived from metastatic human prostate 
adenocarcinoma (Stone at el., 1978). Androgen receptor (AR) protein expression plays a 
critical role in proliferation of DU-145 cells and it is also used to determine prognosis in 
patients with prostate cancer (Yeap et al., 2004). However, various studies have reported 
conflicting results with regards to expression of androgen receptor (AR) protein in DU-145 
cells (Scaccianoce et al., 2003; Alimirah et al., 2006). When growing optimally in vitro, DU-
145 cells have a doubling time of about 48 hour or less (Carey et al., 2009). 
 
The epithelial cervical cancer cells, HeLa, were originally derived from patient Mrs Henrietta 
Lacks (Scherer et al., 1953). Encouragingly, the entire genome of the HeLa cell line has been 
recently sequenced (Callway, 2013; Landry et al., 2013). However, contaminations of the HeLa 
cell line limit the use and the usefulness of these cells (Nelson-Rees et al., 1981; Lacroix, 
2008). Other than contaminations, another problem identified with HeLa cells is the varying 
telomerase activity in different cultures of these cells, which may explain the inability of some 
cells to proliferate (Ivanković et al., 2007). HeLa cell line has a very low expression of p53 




The epithelial breast cancer cell line, MCF-7, which was established in 1973 by the Michigan 
Cancer Foundation, is used widely in in vitro models (Holliday & Spires, 2011). Unlike a more 
aggressive and triple negative (i.e., oestrogen receptor (ER), progesterone receptor (PR) and 
human epidermal growth factor receptor 2 (HER2) negative) MD Anderson’s (MDA-MB231) 
breast cancer cell line, MCF-7s are less invasive and they form tumours in the presence of 
oestrogen (Cailleau et al., 1978; Clarke et al., 1990; Zhang et al., 1991). Other studies have 
reported that MCF-7s lack caspase 3 proteins which play a critical role in apoptosis cascade 
(Kagawa et al., 2001; Mc Gee et al., 2002). Madden and colleagues have reported that MCF-7 
breast cancer cell line has a very low cAMP density as compared to the MDA-MB231s  
(Madden et al., 2011).  Xie and colleagues, in addition, have reported that MCF-7 cell line have 
a low Cyr61 protein; a gene that is associated with the extracellular matrix and angiogenesis 
(Xie et al., 2001). MCF-7s have a doubling time of about 38 hr when growing optimally 
(Sutherland et al., 1983; ATCC, 2012).  
 
Normal breast cancer cell lines, in contrast, have a longer doubling time and finite propagation 
when cultured in vitro, unless immortalised. For instance, HMEC cell line has a doubling time 
of about 46 hr and can be passaged for 32 generations without showing signs of senescence 
(Berthon et al., 1992). Ades and colleagues have, however, reported that HMEC cell line can 
immortalised with PBR-322-based plasmid cloning vector to produce HMEC-1 cell line, which 








1.5  Rationale and Aim 
 
Although there are many currently available anti-cancer therapies, they remain almost 
universally very toxic. For example, cisplatin (Dasari & Tchounwou, 2014) inhibits 
proliferation of both normal and cancer cells, and cause serious nausea and vomiting as well 
as numerous endocrine side effects (Graeppi-Dulac et al., 2014).  Therefore, there is a need for 
effective anti-tumour medicines with fewer adverse effects. Since the treatment of tumours 
places a huge financial burden on patients (Ubel et al., 2013; Meisenberg, 2015), research and 
development into more affordable and efficacious anti-cancer drugs are needed.   
 
Potential exists among as-yet-to-be-explored plants and their extracts and therefore the aim of 
the present study was to investigate this. Since extracts and decoctions from Hypoxis 
hemerocallidea and Helichrysum tenax and Gunnera perpensa are used regularly in many parts 
of South Africa, pure compounds isolated from these plants were investigated. In KwaZulu-
Natal Province (KZN) in particular, extracts from these indigenous plants are commonly used 
as part of traditional remedies for a variety of inflammatory conditions without concrete 
scientific evidence with regards to their effectiveness.  
 
 
1.6  Study Objectives 
 
1.6.1  Screening 
To assess anti-proliferative potential of pure compounds isolated from Hypoxis 
hemerocallidea, Helichrysum tenax and Gunnera perpensa on human cancer cells, namely DU-





1.6.2  Further assessment of potentially useful compounds 
If a potentially promising candidate was found, the next objective would be to determine the 
type of cell death, i.e. whether it causes apoptotic or necrotic cell death of both human cancer 
and normal cell lines.  
 
1.6.3  Determination of possible mechanism of action  
To investigate how a potential compound exerts its cytotoxicity by assessing the activity of 





















2.1  Ethics Approval 
 
The study protocol was approved by the UKZN Biomedical Research Ethics Committee (Ref.: 
BE061/09), please refer to Appendix B.  
 
2.2 Study Design and Screening of Products Using MTT Assay 
 
Since no similar studies had been done using the various compounds investigated in this study, 
MTT assays were initially conducted to find the concentrations which may inhibit proliferation. 
MTT assays were carried out because, at the time, the more sensitive SRB methodology was 
not yet available in this laboratory. Experiments were done on various cancer cell lines, i.e. 
MCF-7 (breast), HeLa (cervical) and DU-145 (prostate). The effectiveness of currently 
available cancer drugs is limited by their toxicity on normal cells (Florea & Büsselberg, 2011). 
Therefore, we also, at this stage, investigated the cytotoxic effects of various compounds on 
normal dermal microvascular endothelial cells (dMVECs).  
 
Various cell lines were exposed for 48 hr to hypoxoside, ent-Beyer-15-en-19-ol and Z-venusol 
isolated from Hypoxis hemerocallidea, Helichrysum tenax, and Gunnera perpensa 
respectively.  The concentrations ranged from 2.34 µg/mL to 2400 µg/mL, dissolved in cell 
specific media. The times were chosen based on the doubling time of each cell line (Sutherland 
et al., 1983; Carey et al., 2009; Sigma-Aldrich, 2006). The concentrations range chosen was 
based on the work of Drewes and colleagues who reported that 750 µg/mL to 8000 µg/mL G. 
perpensa aqueous extracts, in particular, were active against various human pathogens in vitro 





Microscopic examinations were carried out using 100X magnification and 20X objective. 
Images were captured using the Leica Microsystems’ LAS AF Version 2.0.2 (Mannheim, 
Germany). 
 
2.3 Assessment of Proliferation using SRB Assay 
 
Following screening studies, more experiments were carried-out using Z-venusol on breast 
cancer cells (MCF-7s) and on more appropriate and resemblant normal human mammary cells 
(MCF-12s and HMECs). Further tests were not done with other compounds because of their 
limited effectiveness. The MTT assay was replaced with the SRB assay to strengthen 
reproducibility of findings and because of the latter’s superior sensitivity (Skehan et al., 1990). 
 
Various cell lines were exposed for 24 hr, 48 hr and 72 hr to a concentrations range (1.9 µg/mL 
to 240 µg/mL) of Z-venusol. Cisplatin, a known chemotherapy drug against breast cancer, was 
used as a positive control. The concentration range of cisplatin was informed by the findings 
of Smith (1999). The stock solutions of Z-venusol powder and cisplatin were prepared by 
dissolving them in DMSO, ensuring that the final concentration of DMSO that would be in 
contact with cells was equal or less than 0.5% (van Tonder et al., 2014). Cancer and normal 
cell lines were also exposed in the same way to Re-Jooneva™ mixture. This is a commercially 
available product which claimed to contain extracts of G. perpensa. Re-Jooneva™ 
concentration range used was similar to that of Z-venusol and was calculated using information 







2.4 Investigation of Cell Death Pathways 
 
Human cells can die by apoptosis (the so called “good” death), necrosis (the so called “bad” or 
“messy” death), or by a combination of both processes (Newton et al., 2014). Therefore, after 
identifying compounds which caused tumour cytotoxicity, possible pathways of cell death were 
explored for only those which demonstrated potential. 
 
A flow cytometer was used to assess the extent of exposure of phosphatidylserine (PS) protein 
to the outer surface of the cell membrane.  To assess this, fluorescein isothiocyanate (FITC) 
Annexin V apoptosis detection assay was done. After 24 hr incubation, cells were exposed to 
150 μg/mL Z-venusol (for 24 hr and 48 hr). For purposes of comparing findings with a known 
apoptotic drug, cells were also exposed for 4hr to an established apoptotic concentration (0.15 
μM) of camptothecin (Del Bino et al., 1999). The FACS Calibur “JO” E5637 flow cytometer 
was used for analysis. Verifying a possible cytotoxicity pathway due to a potential compound 
was necessary to inform which path to be taken as mechanism of action was to be explored.  
 
Still focusing on what happens at the cell membrane, the direct LDH activity assay (Clontech 
Laboratories, Inc., USA), which gives an unspecific and broad indication of the leakage of the 
cell membrane as the death process begins, was used. After 24 hr incubation, cells were 
exposed to 150 μg/ml Z-venusol for 24 hr and 48 hr. At the end of exposure periods, LDH 
activity was colourimetrically measured in the supernatants. Camptothecin was used as a 
positive control at a necrosis-inducing concentration (4 μM) for 4 hr as per manufacturer’s 




2.5 Possible Mechanism of Action 
To explore possible mechanism of action, activity of IL-6, cAMP and caspases were assessed. 
The activity of IL-6 and cAMP were explored because of regular traditional uses of G. perpensa 
extracts for management of inflammatory conditions and to cause contraction of the pregnant 
uterus (Gumede, 1978).   The activity of caspases were investigated because of established 
apoptotic effects of potential compound on human breast cancer cells in this study. 
 
To investigate the activity of IL-6, cells were exposed for 48 hr to various working 
concentrations Z-venusol; i.e. 37.5 μg/mL and 75 μg/mL. Absorbance, which is directly 
proportional to IL-6 activity, was read in the supernatants using a BioRad (Model 3550) 
microplate reader. The highest final working concentration of the drug used as a positive 
control, pitovastatin, was 1.5 µM (Wang & Kitajima, 2007).  
 
To investigate the activity of direct cAMP, cells were exposed for 48 hr to various working 
concentrations Z-venusol; that is, 37.5 μg/mL, 75 μg/mL, and 150 μg/mL. Absorbance, which 
is inversely proportional to the concentration of cAMP in both the samples and the standards, 
was read in the supernatants using a BioRad (Model 3550) microplate reader. Epinephrine (10 
µM) and propranolol (10 µM), were used separately, in combination and added to the highest 
concentration of Z-venusol for comparison (Kelly et al., 2009; Madden et al., 2011). 
 
To investigate the activity of various caspases, cells were exposed for 48 hr to various working 
concentrations Z-venusol; i.e. 600 μg/mL, 1200 μg/mL and 2400 μg/mL. Absorbance, which 
is directly proportional to the concentration of caspases in both the samples and the standards, 




2.6  Compounds and Drugs Used in this Study 
 
2.6.1 Study Compounds Derived from Medicinal Plants  
Isolation, purification and characterisation of hypoxoside, ent-Beyer-15-en-19-ol and Z-
venusol was carried out in an assay-guided isolation as previously reported (Potgieter et al., 
1998; Khan et al., 2004; Drewes et al., 2006). This was done in order to justify that these pure 
compounds were indeed the main active chemical constituents found in the dried roots of the 
Hypoxis hemerocallidea, fresh air-dried leaves of Helichrysum tenax, and dried roots of the 
Gunnera perpensa. Pure compounds, in dry powder form, were supplied by Professor Siegfried 
Drewes, Department of Chemistry, University of KwaZulu-Natal. 
 
2.6.2 Drugs Used as Positive Controls 
All agents used as positive controls viz., cisplatin, camptothecin, epinephrine, propranolol and 
pitovastatin, were purchased from Sigma-Aldrich.  Initial concentrations of all positive controls 
were based on published data in related studies (Wang & Kitajima, 2007; Kelly et al., 2009; 
Madden et al., 2011) 
 
2.7  Aseptic Technique  
This study used an in vitro cell culture model to investigate the objectives of this study. To 
maintain sterility, separate clean coats were kept in the tissue culture laboratory and latex-free 
gloves were worn all the time when experiments were conducted (Freshney & Liss, 1987; 
Freshney, 2006).  Bench-tops and surfaces of the incubator (Function Line, Heraeus, 
Germany), the centrifuge (Megafuge 1.0R, Heraeus, Germany) and the water-bath (Scientific 
Group, SA), were also swabbed thoroughly with a 5% anti-bacterial solution (Virkon, Antec 




1mL tubes were exposed to UV light for at least a 30 min before use. The microscope along 
with the contents of the biological cabinets was also sterilised with 70% alcohol. At the end of 
daily sterilisation process, the room was allowed to settle for 20 min. All pipette tips and tubes 
used for cell culture were autoclaved at 121ºC at 100 kPa (Speedy Autoclave, SA) for 20 min, 
and thereafter exposed to UV light for 1 hr before use to ensure sterility. To assess 
mycoplasma contamination in the cell cultures, the Myco®Alert Mycosplama Detection Kit 
(Biotech, USA), was used regularly. After every four weeks of continuous use the floor, celling, 
interior wall and windows were cleaned with commercially available disinfectants. 
 
2.8 Cell Lines, Media and Maintenance of Cell Culture  
 
2.8.1  Cell Lines and Media 
The epithelial prostate cancer cells (DU-145) and the epithelial cervical cancer cells (HeLa) 
were grown in (Dulbecco’s Modified Eagle’s Medium (DMEM), purchased from 
Biowhittaker, USA. DMEM was supplemented with 10% Fetal Bovine Serum (FBS), L-
Glutamine and Penicillin Streptomycin Fungizone® (PSF), all purchased from Sigma, St. 
Louis, USA. 
 
The epithelial human breast cancer cells, the Michigan Cancer Foundation-7 (MCF-7s), were 
obtained from Highveld Biological, National Repository of the Cancer Association of South 
Africa. These cells were grown in DMEM (Biowhittaker, USA) supplemented with 10% FBS, 
L-Glutamine and PSF and 0.1% Sodium Pyruvate, all purchased from Sigma, St. Louis, USA. 
 
The dermal microvascular endothelial cells (dMVECs) were sub-cultured using EGM-2 MV 




was supplemented with single aliquots of human epithelial growth factor (hEGF), 10% FBS, 
VEGF, human FGF-ß, heparin, long R insulin-like growth factor 1 (R3-IGF-1), ascorbic acid, 
hydrocortisone and gentamycin sulphate amphotericin ß (GA-1000), all of which were supplied 
together with the basal media. The period needed for sub-culturing was given as 5 – 9 days 
when plated at a density of 5000 cells/cm2.   
 
The human mammary epithelial cells (HMECs) were grown in MEBM (Biowhittaker, USA) 
supplemented with 0.2% Bovine Pituitary Extract (BPE), 0.05% hEGF, 0.05% human insulin 
recombinant, 0.05% hydrocortisone, 0.05% GA-1000 purchased from BioWhittaker, USA. To 
determine the yield of healthy cells, we utilised the trypan blue exclusion dye technique. The 
period needed for sub-culturing was given as 4 – 7 days when plated at a density of 5000 
cells/cm2. 
 
The MCF-12 grown in a mixture of DMEM and Ham's F12 Kaighn's modification. The 
medium is supplemented with 1% PSF, hydrocortisone, cholera toxin, hEGF and insulin from 
bovine pancreas, purchased from Sigma-Aldrich. The supplements were prepared as follows; 
hydrocortisone 100 mg was dissolved in 10 mL water. Then the solution was divided into 50 µL 
aliquots and were stored at -84°C until utilised. One 50 µL aliquot was used for every one litre 
of medium. Cholera toxin 1mg was dissolved in 1mL water. Then the solution was divided into 
100 µL aliquots and were stored at -84°C until utilised. One 100 µL aliquot was used for every 
one litre of medium. Insulin 100 mg was dissolved in 5 mL of sterile water.  Then the solution 
was divided into 500 µL aliquots and were stored at -84°C until utilised. One 500 µL aliquot 





A solution of the EGF were made by mixing 5.7 µL acetic acid with 10 mL of sterile water. 
Thereafter, bovine serum albumin 0.01 g was added to the acetic acid solution. Then, 2 mL of 
EGF solution, which was made by dissolving 0.2 mg EGF in 2 mL of sterile water was added 
into acetic acid solution. The final solution was divided into 200 µL aliquots and stored at 
-84°C until utilised. One 200 µL aliquot was used for every one litre of medium. Then to make 
a DMEM and Ham's F12 Kaighn's mixture, 10 mL DMEM was used to dissolve all 
supplements. Thereafter, additional 490 mL DMEM was added and finally 500 mL Ham’s 
F12 was added. Prior to use, PSF and 10% FBS were added. 
 
2.8.2  Plating and Maintenance of the Cell Lines 
The primary cultures of all cell lines had been purchased and stored at -85C (NuAir ultra-
freezer, Model Nu-9334E, Japan) prior to the commencement of the project.  Cells were 
supplied as cryo-frozen cells in 1 mL aliquots.  Cell culture flasks (200 mL flasks with surface 
areas of 75 cm2, CellStar, USA) containing 8 mL of the appropriate cell-specific medium were 
pre-warmed in a humidified incubator (Function Line) at 37C/5% CO2 for 10 min prior to 
the plating of the cells.  
 
The cryo-frozen vials containing each cell line were removed from storage one by one.  They 
were first thawed in a 37C water-bath (Scientific Group) for 1 – 3 min (or until the ice-crystals 
had melted).  To avoid the possibility of introducing water-borne contamination, care was taken 
so as not to immerse the seals of the vials into the water.  The contents of the vials were 
thereafter plated into the cell culture flasks, labelled with the cell type, date, passage number 
and number of cells, under the sterile environment of the biological cabinet (BioFlow-II, 
Labotec).  To ensure no possible cross contamination occured between the different cell lines, 




allowed before the plating of the next cell line. The same procedure was then followed for the 
next cell line as above.  The culture plates were incubated overnight in the humidified incubator 
(Function Line) at 37C/5% CO2 to allow the cells to adhere.  
 
On the following day, the cells were examined using an inverted microscope (Leica) to ensure 
that the cells had adhered.  The media was removed using glass Pasteur pipettes (Lasec, SA) 
attached to a hand-held electronic pipette (Finnpipette, Thermo-electron Corporation, USA). 
Cell lines were handled one at a time under the biological cabinet.  Appropriate fresh, pre-
warmed medium (8 mL) was then added gently to the flask.  The same protocol was followed 
for the other cell lines once the biological cabinet was swabbed clean with 70% alcohol and a 
half hour had lapsed.  The plates were then incubated again to allow the cells to proliferate.  
The cells were fed and examined microscopically each day to ensure they were healthy, 
growing and multiplying. 
 
2.8.3  Trypsinisation 
The trypsinisation procedure was the same for all cell lines upon reaching ± 80% confluency.  
First, the media was aspirated from the culture flasks under sterile conditions and discarded.  
Thereafter, the cells were gently rinsed with 4 mL of pre-warmed Hanks balanced saline 
solution (HBSS; Clonetics, USA) which was then also aspirated and discarded.  This was 
followed by the addition of 4 mL pre-warmed Trypsin-versene solution (Clonetics). The 
flasks were then incubated for 2 – 3 min to allow the cells to dislodge from the bottom of the 
plate or flask.  Throughout this period, the cells were closely monitored microscopically and 
the trypsinisation process considered successful once most of the cells had retracted their 
plasma membranes towards their cell bodies, the cells appeared shiny and began sloughing off 




volume twice that of the trypsin.  Then cell-solution was aspirated and released back into 
the flask (no more than 5 times) so as to completely dislodge the cells from the surface.  This 
cell suspension was then added to 15 mL centrifuge tubes (Greiner, Germany) and 
centrifuged (Megafuge 1.0R, Heraeus) at 1800 rpm (± 332 x g) for 5 min at room temperature 
to produce a cell pellet.  After the centrifugation step, the supernatant was aspirated and the 
cells gently re-suspended in an appropriate volume of medium (depending entirely on the size 
of the pellet).  Then, the numbers of viable cells were established using the trypan-blue 
exclusion method and the cell numbers quantified to determine plating numbers for the 
propagation of the cell lines.   
 
2.8.4  Cell viability and Cell Counting  
For manual counting of the cells, a haemocytometer was used to determine both the viability 
and the density of cells harvested. Briefly, 25 µL of the cell suspension was added to a 1 mL 
tube (Greiner, Germany) and to this 25 µL of the trypan blue solution (Sigma, USA) was added.  
This was mixed gently with a Gilson pipette, and allowed to stand for no more than 5 min to 
allow any dead cells to take up the dye.  During this time the haemocytometer (Neubauer, 
Assistant, Germany) and coverslip was cleaned thoroughly with 70% ethanol and wiped dry.  
This was to ensure proper loading of the chambers by capillary action.  Next, the trypan blue-
cell suspension solution was gently re-suspended and 25 µL loaded into each chamber of the 
haemocytometer slide using a Gilson pipette.  The cells were allowed to settle briefly and the 
numbers of viable cells (not staining blue) in the 4 squares in each grid were counted under the 
light microscope.  The cell concentration was calculated as follows:  
 
Total cell count (excluding blue-stained cells)   X 104  = Cells/mL 





Depending on the cell numbers, the cells were then used for experiments, passaged further, 
and/or cryo-preserved in order to build up the cell bank.  For sub-culturing, culture dishes were 
pre-warmed in the incubator with their respective cell-specific media.  Optimal cell densities 
used for the 60 mm culture dishes that allowed the cells to grow to approximately 60% 
confluency within 3 – 4 days.     
 
2.8.5  Cryo-preservation of Cells 
The cells that were not used for either experimentation or passaging were cryo-preserved to 
build up a cell bank.  Depending on the volume of the cell suspension left behind, DMSO 
(Sigma) was added to the cell-suspension to give a 10% (v/v) final DMSO concentration.  The 
DMSO was added slowly and the cell suspension left aside for approximately 15 min to allow 
the cryo-preservative to equilibrate within the cells.  The cell suspension was then transferred 
into properly labelled cryo-vials (Corning Costar, USA) and placed into a polystyrene container 
(to slowly reduce the temperature at an approximate rate of 10C/minute) and placed in the ultra-
freezer overnight.  They were then transferred to freezer boxes in the ultra-freezer and stored 
at -850C until such time that more cells were required from storage. 
 
2.9  Details of Cell Proliferation Assays 
 
2.9.1 MTT Assay 
All tumour (DU-145, HeLa and MCF-7) and normal human cells (dMVECs) were plated on 
sterile Corning (Corning Glass Works, USA) 96-well plates at a density of 4000 cells/cm2.  
Plates were incubated at 370C/5% CO2 and 100% relative humidity for 48 hr prior to addition 
of various concentrations of Z-venusol, ent-Beyer-15-en-19-ol and hypoxoside. A conventional 




3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide was reduced to insoluble blue 
formazan crystals by metabolically active cells. Absorbance was measured 
spectrophotometrically and a linear relationship between cell number and absorbance 
established for each cell line.  Any change in absorbance was an indication of change in 
proliferation and the percentage mean differences are calculated as follows: 
 
(mean absorbance (test) – mean absorbance (non-treated control))   X 100
  = Percentage mean difference 
                 Mean absorbance (non-treated control)   
 
  
The absorbance595nm of non-treated cells (control) represented 100% cell proliferation for that 
particular cell line, and was used as a reference. Cells were exposed to the test compounds at 
increasing concentration, up to 4800 µg/mL for both 24 hr and 48 hr treatment periods in order 
to determine the changes in cytotoxicity. The concentration of each compound which would 
inhibit cell growth by at least 50% (IC50) was also established. Dilutions were performed in 
quadruplicate and experiments were repeated five times on all tumour cell lines and three times 
on dMVECs. 
 
2.9.2  SRB Assay 
A conventional SRB assay (Vichai & Kirtikara, 2006) was used to assess the effects of test 
compounds on proliferation of the human normal and tumour cells. Briefly, cells were 
harvested and 80 µL of the cell suspension were seeded into 96-well microplates at a density 
of 2000 cells/well. Cells were then incubated for 24 hr at 37°C/5% CO2 and 100% relative 
humidity to allow for attachment and acclimatisation. Thereafter, appropriate wells were 
exposed to various concentrations of Z-venusol, Re-Joovena™, DMSO (less than 0.5%) and 
4 µM cisplatin for 24 hr, 48 hr and 72 hr. Control cells were incubated with media only. At the 




the cells at the bottom of the 96 well plates which were left in the fridge (at 4°C) for three days. 
Thereafter, the plates were washed three times with distilled water, and left to dry in an oven 
(at 40 C) for about 2 hr. Thereafter, 100 µL of SRB dye (0.057% in 1% acetic acid) was added 
to each well and plates were left at room temperature (protected from light) for 30 min. Then 
plates were washed three times with 400 µL of acetic acid 1% and left in the oven (at 40°C) 
for about 2 hr. Finally, 200 µL Tris buffer (10 mM, pH 10.5) was added and plates were placed 
on the shaker to dissolve the contents of the wells. Absorbance was read using the BioRad 
microplate reader (Model 3550), at 595 nm. Three independent experiments were carried out 
in quadruplicate and no outliers were removed. 
 
2.10 Details of Assays Used to Investigate Cell Death Pathways 
 
2.10.1 Fluorescein Isothiocyanate (FITC) Annexin V Apoptosis Detection Assay  
The FITC Annexin V apoptosis detection assays (BD Biosciences) were conducted as per 
manufacturer’s protocol. Briefly, MCF-7s were harvested and 80 µL of the cell suspension was 
seeded at a density of 5 X 104 cells per well in 12-well culture plates containing 2 mL of 
medium/well. After 24 hr incubation, test wells were exposed to 150 µg/mL Z-venusol (for 24 hr 
and 48 hr). Cells were also exposed for 4 hr to an apoptotic concentration (0.15 µM) of 
camptothecin (Del Bino, et al., 1999), which thus served as a positive control. Afterwards, 
treated and untreated cells were detached using 2 mL of Accutase™ Cell Detachment solution, 
washed with 2 mL of HBSS and then suspended in 1X Binding Buffer solution. Subsequently, 
100 µL of cell suspension (with density of not less than 5 x 104 cells) was transferred into 5 mL 
culture tubes. Thereafter, 5 µL of FITC Annexin V and 5 µL of propidium iodide (PI) dyes 
were added. These suspensions were analysed using a flow cytometer (the FACS Calibur “JO” 




to Appendix C for the FACS Calibur’s instrument settings). Two independent experiments in 
duplicate were carried out. Scatter plots were interpreted as follows: Cells with intact cell 
membrane (viable cells) are scattered in the left lower quadrant of the scatter plot. As the 
process of death begins, cells take up both dyes to varying extents and the predominant uptake 
of one dye indicates the particular mechanism of demise; that is, cells undergoing early necrosis 
absorb only the PI dye and are therefore scattered in the upper left quadrant, while cells 
undergoing early apoptosis are in the lower right quadrant as the FITC Annexin V dye attaches 
to the phosphatidylserine (PS) protein exposed to the outer surface of the cell membrane. Dead 
cells, i.e. cells in late apoptosis and/or necrosis, are scattered into the right upper quadrant 
because they absorb both the PI and the FITC Annexin V dyes. Apoptotic (lower) concentration 
(0.15 µM) of camptothecin, which was originally isolated from the tree Campotheca acuminate 
by Wall and colleagues (Wall et al., 1966), were used as a positive control. 
 
2.10.2 Lactate Dehydrogenase (LDH) Assay 
The LDH cytotoxicity experiment was done as per manufacturer’s (Clontech Laboratories, 
Inc.) instructions. The LDH enzyme is released to the extra-cellular environment when the cell 
membrane breaks. Therefore, the higher the LDH activity (compared to the untreated control 
cells), the more the necrotic cell death. Briefly, cells were harvested and 80 µL were seeded 
into 96-well plates at a density of 2000 cells/well. After 24 hr incubation, appropriate wells 
were exposed to 150 µg/mL Z-venusol and necrosis-inducing camptothecin concentration 
(4 µM) for 4 hr as per manufacturer’s instructions. After centrifuging the plates at 1800 rpm 
(± 332 x g) for 10 min, 100 µL of supernatant were transferred to corresponding optically-
clear, flat-bottom 96-well plates. Thereafter, 100 µL of a freshly-prepared enzymatic reaction 
mixture, containing diaphorase enzyme and tetrazolium salt, was added to each well. After 30 




nm using the Biorad Model 3550 microplate reader. Three independent experiments were 
carried out in quadruplicate.  
 
2.11 Details of Assays Used to Explore Mechanism of Action 
 
2.11.1 Human Interleukin-6 (IL-6) Activity Assay 
The human IL-6 sR ELISA kits, purchased from Sigma, were used as per manufacturer’s 
protocol. Briefly, all reagents were brought to room temperature. Thereafter, 100 µL of each 
standard and sample were added into appropriate wells coated with human IL-6 sR antibodies, 
covered and incubated at 37°C/5% CO2 and 100% relative humidity.  On the following day, 
solutions were discarded and each well was washed 4 times with 300 µL of 1 X Wash Solution. 
Then, 100 µL of prepared biotinylated detection antibody solution was added to each well and 
incubated on the gentle shaker at room temperature for 1 hr. Thereafter, the solution was 
discarded and each well was washed with 1 X Wash Solution as described above. Then, 
100 µL of prepared HRP-Streptavidin solution was added to each well, and incubated with 
gentle shake at room temperature for 45 min. Thereafter, the solution was discarded and each 
well was washed with 1 X Wash Solution as described above. Then, 100 µL of ELISA 
colourimetric 3, 3́,5,5́-Tetramethylbenzidine (TMB) reagent was added to each well, and 
incubated in the dark with gentle shake at room temperature for 30 min. Finally, 50 µL Stop 
Solution was added to each well and absorbance was read using the BioRad (Model 3550) 
microplate reader, at 595 nm wavelengths. The highest final working concentration for a drug 
used as a positive control, pitovastatin, was 1.5 µM (Wang & Kitajima, 2007). Three 





2.11.2 Direct Acetylated Cyclic Adenosine Monophosphate (cAMP) Assay  
The direct cAMP enzyme immunoassay kits, purchased from Sigma were used as per 
manufacturer’s protocol. Briefly, all reagents were thawed to room temperature. The 
acetylation reagent (or solution) was prepared by adding 0.5 mL of acetic anhydride to 1 mL 
of triethylamine. Subsequently, 10 µL acetylation solution was added to every 200 µL of 
standard and sample solutions to enhance the detection of cAMP activity, because there is a 
low expression of β-adrenergic receptors in MCF-7s (Madden et al., 2010). Various 
concentrations (0.078, 0.312, 1.25, 5 and 20 pmol/mL) of standard solution were prepared by 
serial dilution of cAMP solution with 0.1 M HCl. Then, 50 µL of neutralising reagent was 
added into each well of the 96-well-plate coated with goat anti-rabbit IgG antibodies. 
Thereafter, 100 µL of standard solutions and 100 µL of sample solutions added to appropriate 
wells. This was followed by addition of 50 µL of the blue cAMP-Alkaline Phosphatase 
Conjugate into appropriated wells and inoculation of 50 µL of the yellow cAMP EIA antibody 
solution. Then, the plate was incubated on a gentle shaker at room temperature for 2 hr. 
Thereafter, the contents were emptied and the wells were washed three times with a freshly 
prepared 10% wash buffer solution. Then, 200 µL of the p-nitrophenyl phosphatase conjugate 
substrate solution was added to each well and thereafter the plate was incubated at room 
temperature, protected from light, for 1 hr. Finally, 50 µL Stop Solution was added to each well 
and absorbance was read using the BioRad (Model 3550) microplate reader, at 415 nm 
wavelengths.  The measured optical intensity is inversely proportional to the concentration of 
cAMP the samples. Epinephrine (10 µM) and propranolol (10 µM), both purchased from 
Sigma, were used separately, in combination and added to the highest concentration 
of Z-venusol for comparison (Kelly et al., 2009; Madden et al., 2011). Four independent 





2.11.3 Caspase Profiling Assay 
The caspase profiling assay was done as per manufacturer’s (Clontech Laboratories, Inc.) 
instructions. Briefly, cells were harvested and 80 µL were seeded into 96-well plates at a 
density of 2000 cells/well. After 24 hr incubation, appropriate wells with different cell lines 
were exposed 0, 600, 1200 and 2400 µg/mL Z-venusol for 48 hr, 250 000 cells from each plate 
were re-suspended in a chilled 200 µL of appropriate media mixed with 50 µL of Cell Lysis 
buffer and incubated on ice for 10 min. Cell lysates were centrifuged at 1800 rpm (± 332 x g) 
for 10 min at 40C. A 100 µL of supernatant was transferred to 96 well plates containing 5 µL 
of 1 mM caspase substrate (DEVD-AFC). 50 µL of 2 X Reaction Buffer/DTT mixtures was 
added to each well and the plate incubated at 370C for 3 hr in a water bath. Fluorescence was 
read at 355 nm excitation filter and 520 nm emission filter. All experiments were performed in 
quadruplicates and the experiments were repeated three times.  
 
2.12 Statistical Analyses 
GraphPad Prism v5.0 with the freeware package R v2.13.1 was used for statistical 
manipulations and analyses. To determine the IC50 of test compounds, concentrations were 
converted into log10 values to produce non-linear regression concentration–response curves. 
Standard curves of absorbance data of known concentrations were used to extrapolate unknown 
concentrations indicative of activity of protein/messenger of interest. Where applicable, co-
efficient determination (R2) was used to compare relationship co-relation between cell densities 
and concentrations of test compounds. To determine whether any observable differences 
between the treatment group means (with the ± SEM) were statistically significant, either 
Student's T-tests (for normally distributed data) or Mann–Whitney tests (for non-normal 
distributed data) were applied. Findings were considered statistically significant if p-value was 
≤ 0.05. Relevant blanks and vehicle-treated controls (DMSO 0.5% or less) were included. 






























3.1  Cell Viability  
 
Throughout the study period the cell cultures showed no contamination by mycoplasma and 
the yield of healthy cells ranged from 98.5% to 99.0%. 
 
3.2  Screening of Products 
 
3.2.1  Effects on Proliferation Using MTT Assay 
As can be seen in Figure 3.1, hypoxoside resulted in a concentration-dependent increase in 
proliferation in MCF-7 cells. There were a statistically significant (p < 0.001) 38% and 77% 
increases in proliferation at concentrations of hypoxoside 1200 µg/mL and 2400 µg/mL 
respectively after 48 hr exposure. Ent-Beyer-15-en-19-ol, however, had no effect on 
proliferation in MCF-7s at the concentrations studied. Although not statistically significant, 
Z-venusol showed an inhibitory trend and the highest concentration (2400 µg/mL) resulted in 










In cervical cancer cells (HeLa), low concentrations (75 µg/mL) of hypoxoside caused a 
significant 27% decrease (p = 0.05) in proliferation (Figure 3.2). Higher concentrations (600 
µg/mL to 2400 µg/mL) caused an increase (p > 0.05) in proliferation. Similarly, at lower 
concentrations (4.7 µg/mL and 9.4 µg/mL), ent-beyer-15-en-19-ol resulted in a significant 37% 
and 41% (p < 0.05) decreases in proliferation in HeLa cells. As concentrations of ent-beyer-
15-en-19-ol increased, they returned proliferation to normal. However, with Z-venusol there 
was a consistent concentration dependent decrease in proliferation in HeLa cells. The highest 
concentration of Z-venusol studied (2400 µg/mL) resulted in a 21% decrease in proliferation 






As can be seen from Figure 3.3, only the highest concentration (2400 µg/mL) of ent-Beyer-15-
en-19-ol decreased proliferation in prostate cancer cells (DU-145) by only 6%. Similarly, the 
highest concentration of Z-venusol decreased proliferation by only 19%. In dMVECs after 
48 hr exposure, neither ent-Beyer-15-en-19-ol nor Z-venusol, any of concentrations studied, 







3.2.2 Qualitative Microscopic Assessment 
As shown in the (a) panels of Figures 3.5 to 3.8, untreated normal and cancer cells were viable, 
with irregular and spindle shapes (as indicated by dark arrows). For cancer cells, there were 
multitudes of colonies dividing next to each other. However, as expected, in normal cells, there 
were spaces between dividing cells. 
 
In this qualitative assessment, there were more MCF-7 cells showing signs of apoptosis when 
exposed to Z-venusol 2400 µg/mL for 48 hr (Figure 3.5 b) than HeLa (Figure 3.6 b) and DU-
145 (Figure 3.7 b). Apoptotic cells, as indicated by lightening arrows, were “shiny” and the 
majority showed chromatin condensation surrounded by a clear halo. All cancer cell lines 
exposed to ent-Beyer-15-en-19-ol 2400 µg/mL for 48 hr (Figures 3.5c, 3.6c and 3.7c) had very 
few cells with the signs of apoptosis. Samples of dMVECs, exposed to either Z-venusol 2400 
µg/mL or ent-Beyer-15-en-19-ol 2400 µg/mL for 48 hr (Figures 3.8b and 3.8c), had very few 




















As depicted in Figure 3.9, after 24 hr exposure, Z-venusol was without any significant effect 






However, after 48hr exposure (Figure 3.10), Z-venusol caused significant (p < 0.05) inhibition 
in MCF-12 cells, with an IC50 of 51 µg/mL, but it had minimal effect in proliferation of the 
HMECs. At a concentration of 125 µg/mL, Z-venusol showed more cytotoxicity in MCF-7s 







After 72 hr exposure to Z-venusol there was a significant (p < 0.05) concentration-dependent 
inhibition in proliferation of MCF-7s with an IC50 of 53.7 µg/mL (95% CI 29.7 - 96.9 µg/mL), 
(Figure 3.11). The highest concentration of Z-venusol (250 µg/mL), used in this study, caused 
a statistically significant (p < 0.001) inhibition of about 69% in MCF-7s. The pattern of these 
results suggests that more inhibition could be achieved when the concentration is increased 
beyond that which was used.  
 
Similarly, there was statistically significant (p < 0.05) inhibition in proliferation of the normal 
breast cell line, the MCF-12s, with IC50 of 35.6 µg/mL (Figure 3.11).  The highest 
concentration of Z-venusol used in this study caused a statistically significant (p < 0.001) 
inhibition of about 84% in this normal breast cell line. However, Z-venusol did not have any 
significant effects on proliferation in other normal breast cell line, the HMECs, used in this 
study. The highest concentration (250 µg/mL) yielded only 28% inhibition in proliferation in 
these cells Interestingly, the plateau nature of the concentration-response curve, suggests that 
the most cytotoxicity to normal mammary cells occurs with 72 hr exposure to Z-venusol 31.1 
µg/mL. This means that further increases Z-venusol concentration would yield no additional 


















3.3.2 Re-Joovena™  
The highest concentration (250 µg/mL) of G. perpensa extract purported to be in Re-Joovena™ 
caused a 67% (p < 0.001) and 31% (p < 0.05) induction in proliferation in the normal mammary 
cells after 24 hr and 48 hr exposure, respectively (as shown in Figures 3.12 and 3.13). However, 
there were no effects in proliferation of HMEC cells after 72 hr exposure to all the 
concentrations the Re-Joovena™ solution studied, as shown in Figure 3.14. Similarly, none of 
the Re-Joovena™ concentrations showed any effects in proliferation in the MCF-7 cells after 









As was expected, cisplatin caused a statistically significant (p < 0.01) concentration-depended 
inhibition in proliferation in MCF-12 cells, with IC50 of 7.9 µM, 7.0 µM and 1.7 µM for cells 
which were exposed to 24 hr, 48 hr and 72 hr, respectively (Figure 3.15). Significant (p < 0.05) 
concentration-dependent inhibition in proliferation in MCF-7s was seen in cells exposed to 







3.4 Cell Death Pathways  
 
3.4.1  Confirmation of Apoptotic Pathway Using FITC Annexin V Assay  
As shown in Figure 3.17a (LLQ), after 24 hr, 99% of untreated MCF-7 cells were still viable. 
However, 45% of cells which were exposed to 0.15 µM camptothecin showed early apoptosis 
(Figure 3.17b RLQ) after 4 hr exposure period. There was 20.4% and 29.6% induction of early 
apoptosis in cells which were exposed to Z-venusol 150 µg/mL for 24 hr (Figure 3.17c, LRQ) 
and 48 hr (Figure 3.17d, LRQ) respectively. For both exposure periods, the difference between 
cells undergoing early apoptosis (that is Figure 3.17c, LRQ and Figure 3.17d, LRQ) and those 
undergoing early necrosis (that is Figure 3.17c, ULQ and Figure 3.17d, ULQ) was statistically 












3.4.2 Exclusion of Necrotic Pathway Using LDH Assay 
As was expected, there was a significant (p < 0.01) 70% induction of LDH activity in MCF-7 
cells after 4 hr exposure to a high or necrotic concentration (4 µM) of camptothecin (Figure 
3:18). However, the highest concentration (150 µg/mL) of Z-venusol used in this assay resulted 
in 23% (p = 0.31) and 9% induction (p = 0.72) of LDH activity in these cells after 24 hr and 







3.5 Mechanism of Action 
 
3.5.1 Effects of Z-venusol on IL-6 Activity 
Z-venusol caused a concentration-depended inhibition of IL-6 activity in MCF-7s. As can be 
seen in Figure 3.19, the highest concentration (75 µg/mL) of Z-venusol used in this study 
produced a 51% inhibition (p < 0.01) of the IL-6 activity in these cells. As was expected, the 
highest concentration (1.5 µM) of pitovastatin which was used as a positive control, resulted 








3.5.2 Effects of Z-venusol on cAMP Activity 
Low concentrations (37, 5 and 75 µg/mL) of Z-venusol decreased cAMP, was not statistically 
significant (Figure 3.20). Surprisingly, a combination of the highest concentration (Z-venusol 
150 µg/mL) with propranolol 10 µM caused a 34% elevation of cAMP activity (p < 0.05) and 
epinephrine 10 µM caused a 17% reduction of cAMP activity in MCF-7s. However, on its own, 








3.5.3 Effects of Z-venusol on Activity of Caspase 2, 3, 8 & 9 in MCF-7s 
 
As can be seen in Figure 5. 21, generally, Z-venusol caused a decrease in activity of caspases 
2, 3 and 9 in MCF-7s after 48 hr exposure. However, none of these results were statistically 
significant. Surprisingly, there was a 40% and 100% increase in caspase 8 activity in MCF-7s 
which were exposed to Z-venusol 600 µg/mL and 1200 µg/mL, respectively. Unfortunately, 
































4.1 Discussion of Major Findings  
 
Of the compounds screened during this investigation, the first two (hypoxoside and ent-Beyer-
15-en-19-ol) were disappointing from the objective of hoping to find potentially useful cancer 
cures. In particular, hypoxoside was found, at high concentrations (2400 µg/mL), to increase 
proliferation by 65% in breast and by 25% in cervical cancer cells, suggesting that it would be 
likely to cause or exacerbate cancer instead of curing it. This was contrary to several other 
studies that have consistently reported that hypoxoside was pro-apoptotic and that it inhibits 
cell proliferation. For example; Boukes (2010) reported that it inhibits proliferation of cervical 
and breast cancer cells; Ali-Azouaou et al. (2014) reported that hypoxoside and its derivatives 
had activated p53 and it increased expression of caspase 3 in human embryonal 
teratocarcinoma stem cells (the NT2/D1 cells). Similarly, Drewes et al. (2008) reported that 
hypoxoside was active against both malignant and benign prostate cancer cells. However, in 
support of the current findings, Xulu (2013) also reported that hypoxoside, and its active 
derivative known as rooperol, significantly increases cell proliferation of both cancer and 
normal mammary cells in vitro. Further, at a clinical level, Smit et al. (1995) reported that lung 
cancer patients who took hypoxoside 1200 mg to 3200 mg per day did not show any remission 
of the disease and 79% (19 out of 24 patients) died within four months.  
 
There is some evidence of hypoxoside having an effect against human pathogens such as 
Staphylococcus aureus and Escherichia coli (Laporta et al., 2007) and acting as an antioxidant 
(Boukes & van de Venter, 2012; Okem et al., 2015). Antioxidants do have the ability to 
scavenge reactive oxygen/nitrogen species (ROS/RNS) and increase survival of human cells 
(Lu et al., 2010) but also decrease the chance of oncogenic mutations (Diplock et al., 1998). 





Unfortunately, there are no published studies on ent-Beyer-15-en-19-ol for a direct comparison 
with the findings of the current research.  The findings of the current study suggest that it seems 
to play no role in the treatment of breast cancer and prostate cancer because it showed no 
influence on proliferation of MCF-7s and DU-145s. However, its ability to inhibit cell 
proliferation in HeLa lines by almost 50% at concentrations as low as 9.4 µg/mL offers an 
opportunity for further studies. Further, the differences in expression of the vimentin gene, 
which is a part of intermediate filaments (IFs) group occurring in the cytoplasm of many human 
cell, could be used to explain why ent-Beyer-15-en-19-ol showed activity on proliferation of 
HeLa cells and not on proliferation of MCF-7s and DU-145s.  
 
A possible explanation for the different effects on breast and cervical tumours may relate to 
the vimentin gene. This gene is known to induce cell proliferation in cultured cells by 
generating polymeric fibres between microfilament and microtubules during mitosis (Oshima, 
2002; Satelli & Li, 2011). However, a number of studies have reported that MCF-7s lack 
vimentin gene (Pieper et al., 1992), which is incidentally expressed in large quantities in HeLa 
cells (Seegers et al., 1989; Sarria et al., 1990; Yue et al., 2016). Therefore, it could be possible 
that ent-Beyer-15-en-19-ol inhibits proliferation of HeLa cell lines by inhibiting the activity of 
vimentin in these cells while showing low cytotoxicity in the MCF-7s. Other critical 
proliferation genes which are found in low quantities in MCF7s as compared to high quantities 
in HeLa cell line are the Ki67 proteins and the HGF cytokine factors such as claudin (Kiessling 
et al., 1993; Boros & Miller, 1995; MacCallum & Hall, 1999; Martin et al., 2004; Holliday & 
Speirs, 2011; Ma et al., 2015; Zhou et al., 2015).  
 
The most exciting and novel compound discovered during the screening process was Z-venusol, 





breast cancer cells, after 72 hr exposure, in a concentration-dependent manner. There are no 
studies with which to directly compare the findings of these results. However, reports on effects 
of the extracts of G. perpensa on various other cancer cell lines provide an opportunity for 
comparison. For instance, the results of this research support the findings of Simelane and 
colleagues, who recently reported that G. perpensa extracts inhibit cell proliferation (Simelane 
et al., 2012). They reported that crude extracts of the same plant inhibited proliferation of 
hepatocellular carcinoma cells (HepG2) with an IC50 of 222.33 μg/mL and human embryonic 
kidney 293 (HEK293) cells with an IC50 of 279.43 μg/mL both after 48 hr of treatment. By 
comparison, the pure compound, Z-venusol, was more potent against normal cells in the present 
study as it inhibited proliferation of the normal breast cell line (the MCF-12s) with an IC50 of 
51.1 μg/mL after 48 hr exposure. However, there was no significant inhibition of the malignant 
MCF-7s after 48 hr exposure. Direct comparisons are not possible as not only do the cell lines 
differ, but also the exact content of the crude extract is unknown. 
 
Inhibition of cancer cell proliferation with Z-venusol was seen at 72 hr exposure of MCF-7s. 
The IC50 was 53.7 μg/mL. This is slightly more than that specified by the American National 
Cancer Institute guidelines, which sets the acceptable limit of activity for crude plant extracts 
at 30 µg/mL or less (Suffness et al., 1990). Thus, in this setting Z-venusol is unfortunately less 
potent than the ANCI requires for a crude extract. Expressed as μM, the IC50 for Z-venusol is 
165.6 μM compared to 1.2 μM for cisplatin in the same cancer cell line. This means that, 
clinically, higher concentrations of Z-venusol would be needed compared with existing 
chemotherapy medicines such as cisplatin, which causes inhibition of cell proliferation at much 
lower concentrations. Increasing the concentration of Z-venusol would be possible as there was 
no plateau of inhibition of proliferation in MCF-7s. It was only in primary normal human 





This means that if Z-venusol was ever able to be used clinically, the dose might be increased 
higher enough for the attainment of desired therapeutic effects with minimal cytotoxicity on 
normal cells. This is in contrast to a plant-derived drug called vinorelbine, isolated from 
Catharanthus roseus, which Bergh and colleagues, have reported to form “plateaus” as the 
concentration increases beyond a certain point (Bergh et al., 2001). It is also in contrast to 
cisplatin which has a narrow therapeutic index and many other existing chemotherapy drugs 
that are cytotoxic to normal cells (Lee et al., 1992; Hesketh et al., 2002. In clinical settings 
many chemotherapy drugs, such as cisplatin, cause unbearable side effects as the dose is 
increased (Hudis, 1996; McGuire, 1998). 
 
In this study, Z-venusol was more cytotoxic to MCF-12s than to the other to normal cells in the 
study, i.e. the primary human mammary epithelial cells (HMECs). Tetraethylammonium 
(TEA), a non-selective potassium channel blocker across the cell membrane, increases cell 
proliferation and is involved in tumour formation (Marino et al., 1994; Levin, 2012; Berzingi 
et al., 2016). Various studies, however, have reported that TEA expression across normal 
human mammary and breast cancer cell lines varies. For example, Kimura and colleagues have 
reported that HMECs are trypsin-resistant and that they have a very low uptake and a low 
expression of TEA (Dimri et al., 2005; Kimura et al., 2006). On the other hand, there is high 
expression of TEA in MCF-7s (Berzingi et al., 2016) and in MCF-12s (Dhillon, 1999).  The 
difference in the uptake of TEA in the HMECs and in the transformed MCF-7s as well as in 
MCF-12s may explain why Z-venusol is less cytotoxic against the primary human mammary 
epithelial cells as seen in this study. Therefore, it may be hypothesised that the activities of Z-
venusol are mammary cell sub-type specific. The mechanism by which it inhibits cell 
proliferation and causes cell death, may involve blockage of passage of potassium cations 





Cell death can happen by apoptosis (the so called “good” death), necrosis (the so called “bad” 
death), or by a combination of both processes (Karantza & White, 2011; Newton et al., 2014). 
In this study, majority of cancer cells underwent apoptotic cell-death due to exposure to Z-
venusol. Suggesting that this compound interacts with certain cellular proteins and mediators 
in a programmed manner in the demise of cancer cells. Other potential plant-derived 
compounds which have been reported to cause apoptotic cell death in MCF-7s are those 
extracted from Aloe vera (Hussain et al., 2015), plumbagin (Sagar et al., 2014) as well as 
parthenolide isolated from Tanacetum parthenium (Wyrębska et al., 2013).  In contrast, 
Atmaca and colleagues have recently used the Annexin V assay, as was done in this study, and 
reported that crude extracts of Galium aparine caused necrotic, instead of apoptotic cell death 
in MCF-7s (Atmaca et al., 2016).  Numerous recent studies have postulated that both necrotic 
and apoptotic cell death are “programmed” (Galluzzi et al., 2008; Kroemer et al., 2009; Sun et 
al., 2009; Newton et al., 2014). Therefore, knowing the type of cell death that occurred as a 
result of an exposure to compounds is no longer only important for describing the demise as 
“good” or “bad” (Galluzzi et al., 2008; Sun & Peng, 2009). However, identification of the type 
of cell death can also help with selection of an appropriate pathway(s) to follow and to choose 
plausible mediators and proteins to investigate when the exact mechanism of action is being 
explored.  
 
Elucidation of molecular mechanism of action of many drugs is often an arduous and very 
complex process which usually takes years of consistent research to accomplish.  Even for a 
well-known drug such as paracetamol, which has been widely used for over 100 years, its 
mechanism of action has not been fully explained until recently (Graham et al., 1999; Botting 





discover that the observed apoptotic breast cancer cell death, which occurred as a result of 
exposure to Z-venusol, was mediated directly or indirectly by inhibition of IL-6.  
 
Interleukin-6 is one of many pro-inflammation cytokines secreted by macrophages and T-cells 
to stimulate immune response (Scheller et al., 2011). Over-expression of IL-6 has been 
implicated in the pathology of cancer (Krueger et al., 1991; Simpson et al., 1997). Clinically, 
high serum levels of IL-6 is strongly associated with poor prognosis in patients with melanoma 
(Rutkowski, et al., 2002) and metastatic breast cancer (Zhang & Adachi, 1999; Knüpfer & 
Preiss, 2010). Traditional uses of extracts from G. perpensa include management of pain and 
inflammatory conditions such as haemorrhoids and endometritis (McGaw et al., 2005). 
Therefore, the initial suggestion that Z-venusol causes apoptotic cell death by inhibition of IL-
6 correlates well with both the theory of inflammation as a hallmark of cancer pathogenesis 
and with traditional uses of extracts from G. perpensa.  Crude extracts from other plants that 
have been recently shown to cause apoptotic cell death by suppression of IL-6 in MCF-7s are 
those from an indigenous Taiwanese Ipomoea batatas L. Lam herb, commonly called the 
“Purple-Fleshed Sweet Potatoes” (Sugata et al., 2015). Also, as an indirect corroboration of 
the findings of this study, Costantini and colleagues have reported that extracts from Punica 
granatum L. seeds causes apoptosis in these breast cancers cells by inhibition of IL-6 
(Costantini at al., 2014).  
 
Since IL-6 is an up-stream protein, considered to play multifunctional roles in the tumour 
micro-environment, then it triggers numerous middle and downstream mediators to bring about 
uncontrollable cancer cell proliferation (Sağlam et al., 2015). For example, uncontrollable 
proliferation happens when IL-6-stimulation causes activation of the janus kinase (JAK) 





the signal transducers and activators of transcription 3, i.e., STAT3 (Guo et al., 2012). Other 
down-stream proteins that are activated by IL-6-stimulation are the mitogen-activated protein 
kinase (MAPK) and the phosphoinositide 3-kinase (PI3K), which function as the major effector 
of the Ras oncoprotein (Mendoza et al., 2011). Lee and colleagues have recently reported that, 
as a result of an up-stream IL-6-stimulation, withaferin A, isolated from Withania somnifera 
plant, induced apoptosis in MCF-7s through down-stream activation of STAT3  (Lee et al., 
2010). Therefore, in-depth investigations are needed to assess how Z-venusol’s IL-6-inhibition 
affects the STAT3, MAPK, PI3K , Rho kinases and NF-kappaB proteins or even the cAMP 
signalling “cross talk”  described by Irvin et al. (2001). 
 
In this study, initial attempts were made to assess the effects of Z-venusol on cAMP in MCF-
7s. The findings were peculiar and interesting. Several, both in vitro and in vivo, studies have 
reported that cAMP is upregulated in cancer cells (Lang et al., 2004; Powe et al., 2011). Also, 
Pasquier and colleagues have reported that propranolol, a β-adrenergic blocker, improves 
survival in patients with breast cancer (Pasquier et al., 2011). Further, the traditional use of G. 
perpensa has been reported to cause uterine contraction (Varga & Veale, 1997; Kaido, et al., 
1997); possibly by inhibition of β-adrenergic receptors, because β-adrenergic agonist relaxes 
the uterus and increases cAMP. Therefore, we hypothesised that apoptotic cell death in MCF-
7s was as a result of inhibition of cAMP in these cells. Thus, we expected Z-venusol to act like 
β-adrenergic blockers since it contracts the uterus and causes apoptotic cell death in MCF7s. 
However, Z-venusol, in combination with propranolol, resulted in a significant elevation of 
cAMP. 
 
The fact that Z-venusol did not behave like a β-adrenergic agonist in these breast cancer cells 





in various cancer cell lines. Recently, it has been reported that varying β-adrenergic receptor 
density in various breast cancer cells determine whether there is an increase or a decrease of 
cAMP when stimulated or blocked with drugs with an affinity for the β-adrenergic receptors. 
For example, in MCF-7s that are known to have a very low β-adrenergic receptor density, an 
agonist such as adrenaline has no effect on cAMP levels (Madden et al., 2011; Ganz & Cole., 
2011). Also, Vázquez and colleagues have reported that epinephrine decreases the levels of 
cAMP in the MCF-7s through the α2 adrenergic receptor signalling (Vázquez et al., 1999). 
 
At a clinical level too, various studies have reported conflicting findings with regards to the 
benefits of β-adrenergic blockers in patients with breast cancer. For example, other researchers 
have reported no benefits (Shah et al., 2011; Sendur et al., 2012), while some reported that 
these drugs do improve survival (Powe et al., 2010; Barron et al., 2011; Powe et al., 2011). 
Therefore, it is still unclear what role β-adrenergic receptor-stimulation/inhibition and cAMP 
may have played in apoptotic cell death which was induced by Z-venusol in MCF-7s. There 
may even be “cross talk” (Rezzonico et al., 1995; Irvin et al., 2001; Hershko et al., 2002; 
Zivadinovic et al., 2005) between IL-6, which was inhibited, and cAMP, which was elevated, 
in this study. 
 
4.2  Time-line for the Discovery of Z-venusol  
 
This research provides a significant contribution to the growing knowledge on the use of G. 
perpensa. As can be seen in Figure 4.1, there are many other researcher whose work was used 
as invaluable stepping stones for the current research. Briefly, Gumede (1978), provided an 
invaluable record of the maternal use of G. perpensa in the scientific literature as far back as 





scientific study and showed that the traditional claims supporting the traditional use of G. 







However, a milestone was reached in 2004, when Z-venusol was isolated from G. perpensa by 
Khan et al. (2004). Also, in 2004, other researchers such as Steenkamp and colleagues as well 
as Drewes and colleagues reported that G. perpensa extracts showed some activity against 
human pathogens in vitro (Steenkamp et al., 2004; Drewes et al., 2005). The extracts from G. 
perpensa continue to form part of many decoctions and are used widely for traditional 
management of a variety of ailments in KwaZulu-Natal Province, Africa. However, scientific 
evidence to support possible benefits of extracts from this indigenous southern African plant 
against cancer remained tenuous until the current research was carried out and the findings 
presented at national and international conferences, and published in reputable peer-reviewed 
South African journals.   
 
4.3 Originality and Methodological Strength of this Study  
 
This was the first study to have investigated the effects of hypoxoside, ent-Beyer-15-en-19-ol 
and Z-venusol, pure compounds isolated from indigenous southern African plants called H. 
hemerocallidea, H. tenax, G. perpensa, respectively, in various human cancer and normal cells 
in vitro.  The following findings were significant and original: 
 
a) This is the first study to report that Z-venusol causes apoptotic cell death in human 
breast cancer cells. 
b)  This is the first study to report that Z-venusol is less toxic to the primary human 
mammary epithelial cells (the HMECs) and had no significant effect of proliferation of 
dMVEC. 
c) This is the first study to report that Z-venusol inhibits IL-6 activity and that it may act 





d) This is the first study to report that ent-Beyer-15-en-19-ol inhibits proliferation of 
human cervical cancer cells. 
e) This is the first study to report that a widely used decoction, named Re-Joovena™, which 
claims to contain extracts from G. perpensa, has no effect on proliferation of human 
breast cancer cells. 
f) The findings of the present study showed that cell cultures tested negative for 
mycoplasma contamination and cell viability at the beginning of each experiment was 
above 98%. This is a measure of how healthy cells are at the beginning of the 
experiment and cell viability of more than 95% is usually considered acceptable 
(Abcam Plc., 2016; Gibco, 2016). Mycoplasma contamination negatively affects cell 
culture (Uphoff & Drexler, 2011). As a result, numerous guidelines, for the use of cell 
lines in biomedical research strongly recommend that it should not be ignored 
(Geraghty et al., 2014). Therefore, observed effects on proliferation of various human 
cells, in this study, can be attributed directly to products investigated.   
g) Initially, the tetrazolium-based MTT assay was used in this study for the purpose of 
screening the effects of various compounds on a number of human cancer and normal 
cells. However, some MTT experiments in this study were not reproducible. Therefore, 
to strengthen reproducibility of the main findings of this research (McNutt, 2014), 
subsequent assays were carried out using SRB methodology (Skehan et al., 1990). This 
assay has been reported to be more sensitive and reliable especially with screening of 
plant-derived compounds in cancer (Sodde et al., 2015; van Tonder et al., 2015).   
h) To ensure reproducibility, parts of this research was carried out at two different 






Therefore, it can be concluded that the objectives of this study have, by a large degree, been 
achieved, notwithstanding for few study limitations which were beyond practical control.  
 
4.4  Study Limitations  
 
a) Research on hypoxoside, ent-Beyer-15-en-19-ol was limited by the availability of these 
compounds. 
b) Initial investigations for possible mechanism of action of active compound, Z-venusol, 
was carried-out using a single cell line, MCF-7. Since breast cancer is heterogeneous 
(Holliday & Speirs, 2011), the conclusions of this study could be considered limited 
and narrow.   
c) The findings on caspase profiling activity were inconsistent and not reproducible. This 
narrowed the investigation of possible mechanism of action to only two biomarkers, 
among many.   
 
4.5  Recommendations for Further Research 
 
a) More investigations are needed to assess the effects of Z-venusol, e.g., 
 
o On other breast cancer cell lines, which are known to cause a more metastatic 
breast cancer and are difficult to kill, such as the triple-negative MB-231 cell 
line. 
o Since Z-venusol inhibited up-stream mediators (e.g., IL-6), in-depth 
investigations are needed to assess how it affects downstream mediators such 





b) In vivo studies, such as using the nude mice model, are needed to confirm the in vitro 
results and provide an insight into the benefits of Z-venusol in a living systems. 
 
4.6 Recommendations for Change in Public Practice  
 
 
The findings of the current research, although significant, promising and novel, are, at this 
stage, adding new knowledge towards the understanding of the effects of substances used for 
inhibition of cell proliferation, cytotoxicity and the basic science of cancer. They are not yet 
sufficient enough to: 
 
 Recommend clinical studies to determine the effects of either Z-venusol or G. perpensa 
extracts in human beings,  
 Encourage consumption/sale of G. perpensa extracts or Z-venusol compound for the 
treatment (including the so called “traditional treatment”) of cancer.  
 
More importantly, the interpretation of these findings, for now, cannot be extrapolated to 





The idiosyncrasy and heterogeneity of cancer cells transcends into the clinical setting where 
experts differ sharply on the progress made with regards to the fight against cancer. Some 
experts are doubtful (Disis, 2013) while others are very optimistic (Evan, 2015; DeVita & 
DeVita-Raeburn, 2015) about the benefits of chemotherapeutic agents in the battle against this 





for one to be optimistic about the prospects of the many indigenous African medicinal plants’ 
place in the frontlines of the war against cancer. However, it is only “quality science”, which 
often requires many years of hard-work and dedication that can turn cynicism, naïve optimism 
as well as prospects into a reality.  
 
In its own unique way, this study has indeed extended the on-going timeline of unearthing 
the story of the benefits of G. perpensa (in particular). It is anticipated that, in time, the story 
of Z-venusol (isolated from G. perpensa) will emulate (Luna et al., 2015) that of camptothecin 
(isolated from Camptotheca acumenata), as was narrated by Wall et al (1972), Oberlies & 
Kroll (2004), and Liu et al (2015). There are now firm reasons to believe that this compound 
(too) will eventually find its place in the list of highly effective and less toxic chemotherapeutic 
agents used to treat cancer. The objectives of this study have, therefore, not only been fulfilled, 
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Appendix C: FACS Calibur Instrument Settings 
 
  
 
180 
 
 
 
 
 
181 
 
 
  
  
 
